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ABSTRACT 
 
Recent investigations suggest that reducing stearoyl CoA desaturase (SCD) 1 
expression confers protection against obesity and insulin resistance, whereas others 
show that increasing SCD1 expression protects cells from lipotoxicity.  The overall aim 
of this thesis was to establish the role of SCD1 expression in fatty acid metabolism and 
insulin stimulated glucose disposal in skeletal muscle. 
 
In vitro and in vivo studies were conducted to investigate the relationship between fatty 
acid subtype, SCD1 expression and fuel metabolism.  The role of fatty acid subtype on 
fatty acid metabolite accumulation and insulin resistance was initially examined in rats.  
Rats were provided with a low fat diet or a high fat diet consisting of predominantly 
saturated (SAT) or polyunsaturated fatty acids (PUFA).  Rats fed a SAT diet were 
insulin resistant and had increased skeletal muscle diacylglycerol content whereas rats 
fed a PUFA diet retained insulin sensitivity and accumulated triacylglycerol rather than 
diacylglycerol.  Interestingly, SCD1 mRNA and protein content were elevated in SAT 
rats compared with PUFA fed and control fed rats, indicating a possible involvement of 
SCD1 in the aetiology of insulin resistance.  Subsequently, SCD1 expression was 
examined in the skeletal muscle of various rodent models of genetic and diet-induced 
obesity.  SCD1 content was consistently upregulated in the skeletal muscle of obese 
rodents.  
 
To determine whether SCD1 contributes to or protects from fatty-acid induced insulin 
resistance, SCD1 levels were transiently altered in L6 skeletal muscle myotubes.  Short 
interfering (si) RNA was used to decrease SCD1 content and a pcDNA3.1/Hygro-
mSCD1 vector was introduced to increase SCD1 content.  Reducing SCD1 protein 
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resulted in marked esterification of exogenous fatty acids into diacylglycerol and 
ceramide.  Insulin-stimulated Akt (acute transforming retrovirus thymoma) 
phosphorylation and 2-deoxyglucose uptake were reduced with SCD1 siRNA.  
Exposure of L6 myotubes to palmitate abolished insulin-stimulated glucose uptake in 
both control and SCD1 siRNA myotubes.  Transient overexpression of SCD1 resulted 
in triacylglycerol esterification but attenuated ceramide and diacylglycerol accumulation 
and protected myotubes from fatty acid-induced insulin resistance.  Further, these 
changes were associated with reduced phosphorylation of c-Jun Amino-Terminal 
Kinase (JNK) and the inhibitor of IκB kinase (IKK), both of which impair insulin 
signalling.  These studies indicated that SCD1 protects from cellular toxicity in L6 
myotubes by preventing excessive accumulation of bioactive lipid metabolites.  
Collectively, these experiments indicate that increasing SCD1 expression may be a 
protective mechanism designed to prevent insulin resistance in obese phenotypes. 
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CHAPTER 1 
LITERATURE REVIEW 
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1.1 Skeletal muscle fatty acid metabolism 
1.1.1 Introduction 
Skeletal muscles utilise carbohydrates, fatty acids, ketone bodies and amino acids as the 
metabolic substrates to meet the body’s energy requirements.  In non-contracting 
muscle cells glucose and fatty acids are the chief oxidative substrates, contributing 
~10% and 90% respectively, (Dagenais et al., 1976) of the total adenosine triphosphate 
(ATP) turnover.  Long chain fatty acids (LCFA) are the primary lipid energy source for 
skeletal muscle and are stored as triacylglycerol (TAG) within lipid droplets that are 
located in adipose tissue and, to a lesser extent, within skeletal muscle (Terjung & 
Kaciuba-Uscilko, 1986; Gorski, 1992).  The LCFAs are released from TAGs after 
hydrolysis by numerous lipases including hormone sensitive lipase (HSL) and adipose 
triglyceride lipase (Holm et al., 2000; Zimmermann et al., 2004), complexed to albumin 
and enter the circulation for eventual uptake by peripheral tissues such as skeletal 
muscle.  LCFAs are also available to the skeletal muscle as very low density 
lipoproteins and as TAGs in the core of circulating lipoproteins or chylomicrons; 
however, the contribution of these LCFAs to ATP production is considered negligible 
(Sorrentino et al., 1988).   
 
1.1.2 Long chain fatty acid uptake in skeletal muscle 
De novo fatty acid synthesis is limited in muscle fibers (Saggerson et al., 1992; Gaster 
et al., 2005) and intramyocellular triacylglycerol (IMTG) is stored in relatively small 
quantities (~20 mmol/kg dm) (Watt et al., 2003).  Therefore, the bulk of fatty acids 
required for energy production are derived from extracellular sources (Saggerson et al., 
1992).  Fatty acids are released from TAG stores in the adipose tissue by the action of 
HSL and adipose triglyceride lipase (Holm et al., 2000; Zimmermann et al., 2004).  
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After fatty acids are released from adipose tissue, they form a complex with albumin 
because fatty acids are insoluble in blood. 
 
Thus, >99% of the fatty acids carried in plasma are bound to albumin (Arici et al., 
2002).  The fatty acid-albumin complex is transported in the circulation for uptake by 
peripheral tissues, such as skeletal muscle.  Previously, it was assumed that fatty acid 
uptake in muscle tissue occurred via passive diffusion; however, recent investigations 
confirmed that fatty acid transport is a highly regulated process involving numerous 
regulatable proteins (Bonen et al., 2003). 
 
Passive diffusion 
The plasma fatty acid concentration in blood to cytoplasm differs between 200 and 600 
µmol/L and thereby creates a concentration gradient, which acts as driving force behind 
skeletal muscle fatty acid extraction (Van der Vusse & Roemen, 1995).  The 
sarcolemma is composed of two phospholipid membranes.  Absorption of fatty acids to 
the outer layer of the plasma membrane creates a higher concentration of free fatty acid, 
which facilitates fatty acid flux to the inner membrane.  The difference in the ionization 
constants (PKa) results in protonation (ionization) of fatty acid inside the plasma 
membrane (Hamilton et al., 1994).  It is believed that the transfer of fatty acids occurs 
via a flip-flop mechanism in which ionized fatty acids of one leaflet are exchanged with 
unionized fatty acids of another leaflet (Gutnecht, 1988; Schmider et al., 2000) 
indicating the fatty acid affinity towards ionization constant.  Once they come in the 
proximity of inner sarcolemmal membrane the concentration of cytoplasmic fatty acid 
binding proteins (FABPc) facilitate the fatty acid to undergo desorption to cross the 
membrane and bind to it to reach intracellular sites for utilisation (Hamilton, 1998).  
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Although passive diffusion contributes to sarcolemmal uptake of fatty acids, it is now 
clear that protein-mediated uptake is also involved in this process. 
 
Protein-mediated uptake 
Protein mediated transport involves various membrane associated proteins including the 
40 kDa plasma membrane bound fatty acid binding protein (FABPpm), the 53 kDa 
native, non-glycosylated fatty acid translocase (FAT/CD36, the rat analogue of human 
CD36) and the 63 kDa fatty acid transport protein (FATP) 1-5.  Studies in cell culture 
demonstrate that each of these proteins can independently increase fatty acid transport 
when overexpressed (Bonen et al., 2002). 
 
 In mammals, the bulk of fatty acids dissociate from albumin upon entry to the 
interstitial space and bind with FABPpm, which facilitates transport of fatty acid across 
the plasma membrane (Van der Vusse et al., 1998).  FAT/CD36 is present at the plasma 
membrane and also appears to be translocated from an intracellular location to the 
plasma membrane in response to insulin and contractions (Bonen et al., 2003).  
FAT/CD36 transports fatty acids across the lipid bilayer of the plasma membrane 
(Abumrad et al., 1993; Koonen et al., 2005) and  it appears as though FAT/CD36 and 
FABPpm may act in concert to facilitate this process; however, the molecular 
mechanisms are unresolved (Bonen et al., 2003).  There is also evidence that 
FAT/CD36 is located in subsarcolemmal and intermyofibril fractions of highly purified 
mitochondria, and functional assessment suggests that FAT/CD36 may translocate to 
the mitochondria and facilitate fatty acid oxidation (Campbell et al., 2004).  The FABPc  
(Bass, 1988; Glatz et al., 1988; Veerkamp & van Moerkerk, 1993), binds to the fatty 
acid and activate it to form fatty acyl-CoA in presence of acyl-CoA synthase (ACS).  
This process facilitates the binding of fatty acyl-CoA to acyl-CoA binding protein, 
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which can transport the fatty acyl-CoA to various cellular locations before dissociation 
and entry of fatty acids into metabolic pathways including oxidation and esterification.  
FATP is an integrated bifunctional membrane protein, which is involved with fatty acid 
transport and possesses catalytic characteristics to convert the fatty acids into fatty acyl- 
CoA (Coe et al., 1999; Herrmann et al., 2001).  FATP co-expression along with 
FAT/CD36 suggests its involvement with FAT/CD36 could contribute fatty acid uptake 
in muscles (Brinkmann et al., 2002; Gimeno et al., 2003).  The activation of fatty acids 
into acyl-CoA by the intrinsic ACS of FATP is still under investigation (Hall et al., 
2003).  
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Figure 1.1 Schematic representation of fatty acid transport in skeletal muscle across 
endothelium and plasma membrane.  Fatty acid (FA), plasma membrane fatty acid 
binding protein (FABPPM), fatty acid translocase (FAT/CD36), fatty acid transport 
protein (FATP), acyl-CoA synthase (ACS), cytosolic fatty acid binding protein 
(FABPC), acyl CoA binding protein (ACBP), fatty acyl-CoA (FACoA). 
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1.1.3 Fatty acid oxidation 
Upon entry to the cytoplasm, LCFAs are directed to oxidation for the production of 
ATP, or to storage as intracellular signalling molecules, phospholipids and triglycerides.  
The LCFAs entering the cytoplasm are coupled with coenzyme A in the presence of 
ACS to form fatty acyl-CoA.  ACS appears to play an important role in regulating fatty 
acids into oxidative and synthetic pathways as suggested by its cellular location on the 
outer mitochondrial surface and plasma membrane, and proximity to proteins involved 
with esterification (Iijima et al., 1996).  
 
Fatty acyl-CoAs are oxidized to acetyl-CoA in the mitochondria.  Although short-chain 
fatty acids (C4-C10) can diffuse through the mitochondrial membrane, long LCFA-
CoAs require a carrier to cross the mitochondrial membranes.  To overcome the 
mitochondrial membrane barrier, the long chain fatty acyl-CoA esters are adapted to a 
carnitine-dependent shuttle mechanism (Bremer, 1983).  Carnitine palmitoyl transferase 
(CPT)1 is an enzyme which is present in outer mitochondrial membrane and is 
considered a rate-limiting step to LCFA-CoA flux into the mitochondria (McGarry & 
Brown, 1997).  CPT1 is situated on the inner surface of the outer mitochondrial 
membrane and converts acyl-CoA (long chain fatty acid) to acylcarnitine.  Acylcarnitine 
is then transported across the inner mitochondrial membrane by carnitine-acylcarnitine 
translocase in exchange for carnitine.  After reaching the mitochondrial matrix, 
acylcarnitine is exchanged for free carnitine in the presence of CPT2 to release free fatty 
acyl-CoA into the mitochondrial matrix.  Along with the CPT system, a recent 
investigation has suggested that FAT/ CD36 can transport fatty acids across the 
mitochondrial membranes (Campbell et al., 2004) and thereby act as an alternate 
pathway to transfer LCFAs into the mitochondria.  
   
 10 
Inside, the mitochondria fatty acyl-CoA undergoes β-oxidation, which consists of a 
series of dehydrogenation, hydration, oxidation, and thiolysis reactions to ultimately 
form acetyl-CoA.  The dehydrogenation reaction catalyses the conversion of fatty acyl-
CoA to enoyl-CoA by acyl-CoA dehydrogenase.  Enoyl-CoA is then hydrolysed by 
enoyl-CoA hydratase to 3-L-hydroxyacyl-CoA, which undergoes an oxidation reaction 
catalysed by 3-L-hydroxyacyl-CoA dehydrogenase to form β-ketoacyl-CoA.  In the 
final step β-ketoacyl-CoA thiolase catalyzes the β-ketoacyl-CoA to form acetyl-CoA.  
The acetyl-CoA can then enter the Krebs cycle to produce ATP.  
 
1.1.4 Fatty acid esterification 
TAGs are the main storage forms of energy in muscle cells.  Excess fatty acids are 
stored as TAGs in the form of lipid droplets in cells.  Fatty acyl-CoAs in the cytoplasm 
serve as the major precursor to TAG synthesis, which results from a series of reactions 
described as the Kennedy pathway.  The two major enzymes involved in this process 
include glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol acyltransferase 
(DGAT).  Excess fatty acyl-CoAs are esterified to glycerol-3-phosphate by GPAT to 
form lysophosphatidate.  GPAT activity is increased by insulin (Saggerson et al., 1992), 
thyroid hormone (Baht & Saggerson, 1988) and transcriptionally activated by sterol 
reglulatory elementary binding proteins-1 (SREBP-1) (Brown & Goldstein, 1997).  
Conversely, GPAT activity is inhibited by glucagon via increasing intracellular cAMP 
levels (Sul et al., 2000).  
 
 Lysophosphatidate is catalysed by lysophosphatidic acid acyl transferase (LPAAT) to 
form phosphatidate, which acts as precursor in the synthesis of TAG along with 
phospholipids.  It is hydrolysed by phosphatidate phosphohydrolase (PPH-1) to form 
diacylglycerol (DAG).  PPH-1 is also upregulated by insulin (Saggerson et al., 1992) 
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and thyroid hormone (Baht & Saggerson, 1988), while glucagon counter-regulates these 
other hormonal actions.  DGAT then acylates DAG to form TAG and is considered a 
key regulator of TAG biosynthesis.  Like other enzymes in the Kennedy pathway, 
DGAT is hormonally regulated, thyroid hormone and insulin increase DGAT activity 
and glucagon antagonises this effect (Coleman et al., 2000). 
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Figure 1.2 Schematic representation of TAG esterification.  Lysophosphatidic acid acyl 
transferase (LPAAT), phosphatidate phosphohydrolase (PPH-1), glycerol-3-phosphate 
acyltransferase (GPAT), diacylglycerol acyltransferase(DGAT), acyl CoA synthase 
(ACS), diacylglycerol (DAG), triacylglycerol (TAG).  
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1.1.5 Triacylglycerol hydrolysis 
TAG is a complex energy fuel stored primarily in adipose tissue, and to a lesser extent 
in skeletal muscle.  In adipose tissue, TAGs are hydrolysed by numerous lipases 
including adipose triglyceride lipase, HSL and monoglyceride lipase (Holm et al., 2000; 
Zimmermann et al., 2004).  In skeletal muscle, TAGs and DAGs are known to be 
hydrolysed by HSL, and studies using neutralising antibodies suggest the existence of 
other neutral lipases that are important for basal hydrolysis (Langfort et al., 2000; Watt 
& Spriet, 2004; Watt et al., 2004).  HSL is controlled by β-adrenergic and contraction 
related mechanisms by phosphorylation at various serine residues (Langfort et al., 2000; 
Watt et al., 2005; Watt et al., 2006b).  The fatty acids produced in this reaction are 
utilised for cell functions, including oxidation and re-esterification, and the liberated 
glycerol is transferred to liver for glucose synthesis or subjected to TAG resynthesis. 
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Figure 1.3 Schematic representation free fatty acid release during triacylglycerol 
hydrolysis.  Adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), 
monoglyceride lipase (MGL), triacylglycerol (TAG), diacylglycerol (DAG), 
monoacylglycerol (MG) and fatty acid (FA).  
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1.2. Fatty acid metabolites and insulin resistance 
1.2.1 Introduction 
Skeletal muscle is quantitatively the most important tissue for insulin and non-insulin 
stimulated glucose uptake, contributing between 75-95% of total uptake (Baron et al., 
1988a).  Insulin facilitates glucose uptake and other metabolic activities in tissues and 
the reduced ability of these activities lead to insulin resistance.  Insulin resistance is a 
condition in which the cells of the body become resistant to the effects of insulin, that 
is, the normal response to a given amount of insulin is reduced. As a result, higher 
levels of insulin are needed in order for insulin to induce its effects.  Various factors are 
attributed to the aetiology of insulin resistance.  The close association of lipid 
oversupply and insulin resistance is well established in various tissues and have been 
reviewed previously (Griffin et al., 1999; Boden et al., 2001; McGarry, 2002).  In cases 
where free fatty acid availability is increased, fatty acid metabolites including DAGs, 
ceramides and LCFA-CoA are proposed to reduce insulin sensitivity by interfering with 
various aspects of the insulin signalling cascade.  Insulin resistance is the common 
preceeding feature of type 2 diabetes. 
 
1.2.2 Insulin signal transduction 
Insulin induces the transport of glucose via activation of glucose transporter proteins 
(GLUT).  They are transmembrane proteins categorised as GLUT1 to GLUT 12 (Linden 
et al., 2006) and differ from each other in terms of tissue distribution, biochemical 
properties, regulatory mechanisms and physiological actions (Bell et al., 1990).  
Skeletal muscle is considered as the major site for blood glucose regulation by insulin.  
Among different glucose transporter isoforms, GLUT1 and GLUT4 are the isoforms 
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seen in skeletal muscle but GLUT4 is expressed in major portion and plays a significant 
role in insulin signalling.  It commences with binding of insulin to its receptor.  The 
insulin receptor consists of two extracellular alpha (α) and transmembrane beta (β) 
subunits (Muller-Wieland et al., 1993) with intrinsic tyrosine kinase activity.  Insulin’s 
binding to the α subunit induces autophosphorylation of the β-subunit on tyrosine 
residues resulting in the activation of the receptor.  The insulin receptor substrate, a 
member of protein family that appears in six different isoforms (Huang et al., 2005), 
then associates with the insulin receptor.  Insulin receptor substrate 1(IRS-1) is believed 
to be involved considerably in the regulation of glucose homeostasis in skeletal muscle 
and IRS-2 as an alternative (White & Kahn, 1994; Cai et al., 2003; Huang et al., 2005).  
This event induces the signal downstream via activation of phosphotidylinositol-3-
kinase that binds to IRS-1 through its p85 subunit.  This event phosphorylates the 
secondary messengers, phosphatidylinositol 3, 4-biphosphate and phosphatidylinositol 
3, 4, 5-triphosphate (PIP3) then activates phosphoinositide-dependent kinase-1 (PDK-1), 
which subsequently phosphorylates protein kinase B (PKB, also known as Akt) 
(Burgering & Coffer, 1995) and the atypical protein kinase C (aPKC) isozymes (aPKC 
ζ, ι) (Good et al. 1998).  Akt along with atypical PKCs, zeta (ζ) and lambda (ι), are 
involved in the translocation of GLUT4 to the plasma membrane (Schmitz-Peiffer, 
2000).  Limited evidence suggests that other PKC isozymes contribute to GLUT4 
translocation (Braiman et al., 1999; Cooper et al., 1999).  Akt is also involved in 
glycogen synthesis by inactivating and phosphorylating glycogen synthase kinase-3, 
which inhibits the phosphorylation of glycogen synthase, thereby enhancing glycogen 
synthesis from intracellular glucose.  
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Figure 1.4 Schematic representation of intracellular proteins involved with binding to 
insulin receptors during GLUT4 translocation across the cell membrane.  
Phosphotidylinositol-3-kinase (PI3-K), phosphatidylinositol (3,4,5), triphosphate (PIP 
3,4,5), protein kinase B (PKB or Akt), phosphatidylinositol (4,5)biphosphate (PIP 4,5), 
atypical protein kinase C (a PKC), phosphoinositide-dependent protein kinase-1 (PDK-
1), Insulin receptor substrate1 (IRS-1). 
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1.2.3 Fatty acid metabolism in obesity and insulin resistance 
Fatty acid metabolism is regulated by genetic, nutritional and hormonal factors (Lewis 
et al., 2002).  Fatty acid metabolism in skeletal muscle is an essential factor that 
contributes to insulin resistance and obesity.  Disturbances in skeletal muscle fatty acid 
metabolism include defects in skeletal muscle fatty acid transport (Kelley et al., 1999; 
Bonen et al., 2004) oxidation (Kelley et al., 1999) and increased TAG storage (Bonen et 
al., 2004).  Generally in muscle, the delivery of free fatty acids is balanced by 
esterification into TAGs and other intracellular lipid pools and oxidation.  One 
disruption in obese and diabetic conditions is an increase in circulating plasma fatty 
acids, which most likely reflects impaired lipolytic pathways in adipose tissue (Large & 
Arner, 1998).  It appears that the insulin resistance commonly observed in these 
individuals diminishes the inhibitory effects of insulin on HSL, which in turn leads to 
increased lipolysis and plasma free fatty acid levels (Gelding et al., 1995; Eriksson et 
al., 1999).  Skeletal muscle fatty acid transport is another other factor involved in the 
dysregulation of fatty acid metabolism.  LCFA protein transporters are now considered 
important in explaining the aberrations of fatty acid transport in obese and insulin 
resistance conditions.  It appears that FABPpm function is not defective in obesity, 
whereas FAT/CD36 is associated with an increased transport rate and fatty acid 
esterification in obese subjects compared to controls (Bonen et al., 2004).  They also 
revealed that the expression of fatty acid transporters is unchanged; however, there is 
more FAT/CD36 at the plasma membrane consistent with increased fatty acid uptake 
(Bonen et al., 2004).  Furthermore, the increased LCFA transport rate with diminished 
fatty acid oxidation causes TAG accumulation in skeletal muscle (Bonen et al., 2004). 
 
Obesity is also characterised by a decreased capacity for mitochondrial fatty acid 
oxidation.  Lower carnitine palmitoyl transferase (CPT) activity and oxidative enzyme 
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activity is reported in obesity versus lean control subjects (Simoneau et al., 1999) which 
was consistent with reduced tracer determined rates of fatty acid oxidation (Kelley et 
al., 1999).  In a recent study by Kim and co-authors, defective CPT activity contributed 
to reduced oxidation in obese skeletal muscle (Kim et al., 2000).  Collectively, these 
abnormalities in fatty acid metabolism leads to excessive storage of intramyocellular 
triglyceride (IMTG) accumulation, and other fatty acid metabolites, which leads to 
insulin resistance (Phillips et al., 1996; Pan et al., 1997; Watt et al., 2006a). 
 
1.2.4 Mechanisms of fatty acid induced insulin resistance 
It is well established that the accumulation of intracellular lipids is associated with 
insulin resistance (McGarry, 2002).  Although it was long thought that TAG caused 
insulin resistance (Storlien et al., 1991; Pan et al., 1997; Krssak et al., 1999), this seems 
unlikely because TAG is sometimes elevated in instances where skeletal muscle is 
actually insulin sensitive (Bruce et al., 2003).  It is now apparent that the generation of 
lipid intermediates such as LCFA-CoA, DAGs and ceramides are more likely to 
mediate these defects in insulin signalling. Indeed, these metabolites are often elevated 
in the skeletal muscle of obese and individuals with type 2 diabetes.  
 
Long chain fatty acyl- CoA  
LCFA-CoAs are a major link between increased lipid availability and impaired lipid 
metabolism.  As discussed, these are the activated forms of intracellular free fatty acids 
that are converted in the presence of ACS into LCFA-CoA.  The increased LCFA-CoA 
pool may interfere with insulin signalling via activating PKC theta(θ) activity (Orellana 
et al., 1990; Kasahara & Kikkawa, 1995), which is proposed to inhibit insulin signal 
transduction via serine phosphorylation at 1101.  This limits tyrosine phosphorylation 
and subsequent downstream signalling.  Alternatively, LCFA-CoA can be esterified into 
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DAGs (Nishizuka, 1995) or combined with serine to form ceramides (Schmitz-Peiffer, 
2002), both known inhibitors of insulin action.  LCFA-CoAs are also believed to 
interfere with a variety of cellular processes that affect insulin mediated glucose 
transport in skeletal muscle, such as inhibiting hexokinase, the first enzyme of 
intracellular glucose metabolism, which results in alterations of glucose transport into 
the tissue (Thompson & Cooney, 2000). 
 
Diacylglycerol 
DAGs are elevated in the skeletal muscle of obese, insulin resistant phenotypes 
(Schmitz-Peiffer et al., 1997).  Elevated DAG levels are thought to interfere with 
insulin signalling by activation of PKC (θ, δ, β2) isoforms (Schmitz-Peiffer, 2002).  
PKC β1 and β2 inhibit the tyrosine kinase activity of the insulin receptor (Bossenmaier 
et al., 1997) and other studies in skeletal muscle showed that the activated PKC, in 
presence of DAGs, induces phosphorylation on serine and threonine residues of the 
insulin receptor, which results in diminished tyrosine kinase activity and insulin 
resistance (Itani et al., 2000).  The role of PKC in lipid induced insulin resistance is 
further confirmed by reduced insulin stimulated phosphatidylinositol-3-kinase activity 
(Griffin et al., 1999).  The decrease in phosphatidylinositol-3-kinase activity was 
hypothesised to be mediated by phosphorylation on IRS-1 Ser 307, and subsequent 
decreases in IRS-1 tyrosine kinase activity (Yu et al., 2002).  However, PKC theta (θ) is 
not likely to directly phosphorylate IRS-1 at Ser307 because it is not a proline-directed 
kinase.  Instead, it is possible that PKCs may activate JNK and IKKβ, known kinases 
for Ser 307.  This would be consistent with studies demonstrating that fat-induced 
insulin resistance is blocked in JNK1 and IKKβ knock-out mice (Yuan et al., 2001; 
Hirosumi et al., 2002).  Others have demonstrated that PKC θ phosphorylates IRS-1 at 
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serine 1101 blocking IRS-1 tyrosine phosphorylation and downstream activation of the 
Akt pathway (Yu et al., 2002; Li et al., 2004).   
 
Ceramide 
Ceramides are generated either by de novo synthesis from serine and palmitoyl-CoA 
(Merrill & Jones, 1990) or hydrolysis of sphingomyelin in the presence of 
sphingomyelinase.  Ceramides are elevated in the skeletal muscle of insulin resistant 
rodents (Turinsky et al., 1990; Lessard et al., 2004) and humans (Adams et al., 2004; 
Straczkowski et al., 2004).  Ceramides interfere with insulin signalling at the level of 
Akt.  Ceramides dephosphorylate Akt at the catalytically important Ser 473 site via 
activation of ceramide activated protein phosphatase, which is a member of protein 
phosphatase family (Begum et al., 1996).  Ceramide also exerts a negative effect on Akt 
through the activation of the PKC ζ (Andjelkovic et al., 1996), which is thought to 
prevent translocation of Akt to the plasma membrane secondary to Akt Ser 32 
phosphorylation (Powell et al., 2004).  Others studies have suggested that ceramides can 
interfere with signalling by inhibiting tyrosine phosphorylation of IRS-1 (Summers & 
Nelson, 2005), although further work is required to confirm these events.  Irrespective, 
fatty acid exposure results in ceramide accumulation, which inhibits insulin stimulated 
glucose uptake, GLUT4 translocation (Summers et al., 1998) and glycogen synthesis in 
muscle cells (Hajduch et al., 2001), thus demonstrating a causative role in insulin 
resistance.  
 
Serine/Threonine kinases are involved with fat-induced insulin resistance 
 c-Jun Amino-Terminal Kinase (JNK) is activated in presence of free fatty acids and 
inflammatory cytokines and are elevated in obesity and type 2 diabetes (Hotamisligil et 
al., 1996; Griffin et al., 1999).  JNK phosphorylates IRS-1 at Ser 307 (Aguirre et al., 
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2000) and the absence of JNK significantly improves insulin sensitivity and enhances 
insulin receptor signalling capacity in obese rodent models (Hirosumi et al., 2002).  IκB 
Kinase β (IKKβ) is a serine kinase identified as a proximal element of the pro-
inflammatory IKK/IkB/NFkB pathway. Studies in obese and insulin resistant mice 
demonstrate increased liver IKKβ activity (Cai et al., 2005), which is likely to result in 
phosphorylation on IRS-1 Ser307.  Studies in mice with targeted disruption of liver 
IKKβ show that IKKβ acts as negative regulator in insulin signalling by reducing the 
association of IRS-1 with p85 subunit of phosphoinositol-3-kinase and Akt activation 
(Arkan et al., 2005; Cai et al., 2005).  Others showed that inhibition of IKK activity by 
administration of salicylates prevents acute fat-induced insulin resistance in rodents and 
improves insulin sensitivity in type 2 diabetes patients (Kim et al., 2001b; Hundal et al., 
2002).  More recently, studies in L6 myotubes extend on these observations and 
demonstrate that NFkB activation, which is downstream of IKK, is an important 
mechanism of lipid-induced insulin resistance (Sinha et al., 2004).  Thus, activation of 
the NFkB pathway by fatty acids can induce insulin resistance.  
 
1.2.5 Acute fatty acid treatment and insulin resistance 
In the past few years, much research has focused on establishing the interaction between 
lipid oversupply and insulin resistance.  Lipid oversupply is defined as elevated plasma 
free fatty acids, which is often observed in obese and insulin resistant patients (Boden & 
Chen, 1995).  Randle and co workers predicted a long time ago that elevated glucose 
stimulates insulin secretion and consequently controls the availability of FFA release 
from tissue depots to avoid the competition for substrate utilization in muscle.  When 
plasma FFA levels are elevated, fatty acid oxidation is also increased resulting in 
reduced glucose uptake and oxidation.  Thus, excess fatty acids may induce insulin 
resistance by its inhibitory action on pyruvate dehydrogenase, which further inhibits a 
 23 
series of enzymes involved in glucose uptake and ultimately leading to feedback 
inhibition and reduced glucose uptake (Randle et al., 1963; Randle et al., 1964).  Recent 
investigations have addressed the issue of lipid oversupply by acutely increasing plasma 
free fatty acids (i.e: to 1.5 to 2 mM) by infusing a TAG emulsion with heparin for 
several hours.  Using this technique Roden et al., (Roden et al., 1996; Roden et al., 
1999) demonstrated that lipid oversupply reduced insulin mediated glucose transport 
/phosphorylation in skeletal muscle of healthy humans.  It is apparent that the increased 
plasma fatty acid concentration observed using this technique is associated with  the 
accumulation of several fatty acyl-CoA metabolites including  ceramide (Watt et al., 
2005; Watt et al., 2006b), LCFA-CoA and DAGs (Yu et al., 2002).  This is associated 
with IRS-1 serine 307 phosphorylation and reduced glucose transport.  Furthermore, the 
defective insulin action could not be reversed despite the fact that cells were exposed to 
pharmacological insulin concentrations, thus demonstrating that lipid oversupply is a 
powerful mediator of insulin resistance (Yu et al., 2002).   
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Figure 1.5 Schematic representation of possible mechanisms of intramuscular lipid 
metabolite interference of insulin signalling.  Fatty acid(FA), fatty acyl-CoA (FA-CoA), 
diacylglycerol (DAG), triacylglycerol (TAG), carnitine palmitoyl transferase (CPT), 
insulin receptor substrate (IRS-1), phosphatidylinositol -3-kinase (PI-3-K), 
phosphatidylinositol- dependent kinase (PDK), protein kinase B (akt/PKB), novel 
protein kinase C (nPKC). LCFA are incorporated into ceramide and DAG, which 
directly inhibit insulin signal transduction at Akt and IRS-1 respectively. 
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1.2.6 High fat diet induced insulin resistance  
There is now excellent evidence to show that chronic high fat feeding induces insulin 
resistance.   Various genetic and nutritional factors are believed to contribute to insulin 
resistance.  Among the nutritional factors, high fat diet and its widespread availability 
plays the major role in inducing insulin resistance.  Various studies have suggested an 
inverse relationship between fat content and insulin sensitivity in various models 
(Krssak et al., 1999; Boden et al., 2001; Kim et al., 2001a).  Rodents are used as the 
common model of research to investigate the relationship between high fat feeding and 
insulin resistance.  Most diet studies have found that high fat feeding results in defective 
insulin signalling (Hansen et al., 1998; Anai et al., 1999; Kim et al., 2004a; Herr et al., 
2005; Gao et al., 2006).  In insulin signal transduction, IRS1 and IRS2 mediate PI3-
Kinase activation which plays an important role in GLUT4 translocation and glycogen 
synthesis.  A study conducted by Anai and his group demonstrated that high fat feeding 
in rodents impairs PI 3-Kinase activation in muscle and adipose tissue (Anai et al., 
1999).  According to this study, high fat diets result in decreased phosphorylation of 
IRS1 and IRS2, which further decreased IRS association with PI 3-Kinase (Anai et al., 
1999).  These findings are further confirmed by another study as high fat diet impairs 
stimulation of glucose transport in muscle (Hansen et al., 1998).  It was explained in 
this study that a high fat diet leads to decreased insulin-stimulated tyrosine 
phosphorylation in muscle and defective insulin receptor signalling with impaired 
GLUT4 translocation, which ultimately results in impaired glucose transport.  Another 
important aspect in insulin resistance is activation of PKC isoforms in response to fatty 
acid derivatives and DAG.  This activation results in inhibition of insulin signalling by 
inducing serine phosphorylation of IRS1, which inhibits tyrosine phosphorylation of 
IRS1 and downregulates the activation of PI3-Kinase (Kim et al., 2001b; Gao et al., 
2006).  These above studies indicate that fatty acid metabolites may interfere with 
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insulin signalling to induce insulin resistance.  In a recent study the relationship 
between intramuscular fat content and insulin resistance was investigated (Kim et al., 
2004b).  According to this study, consumption of a high fat diet induces the expression 
of FATP, which leads to elevated fatty acid uptake into cells for accumulation of fatty 
acid metabolites and induce insulin resistance.  
 
It also appears that the type of dietary fatty acid is equally important in this process.  A 
classic study by Storlein and colleagues showed that rats fed saturated and unsaturated 
diets become profoundly insulin resistant, whereas substituting a small fraction of the 
diet with fish oil largely prevents this effect (Storlien et al., 1991).  The variable effects 
of high fat diets has gained recent attention because the consumption of different fat 
content is thought to produce different fatty acid metabolites, some of which are linked 
to insulin resistance.  A recent study in skeletal muscle cells showed that accumulation 
of different fatty acids may alter insulin function in skeletal muscle in vitro (Thompson 
& Cooney, 2000).  According to these authors, skeletal muscle cells treated with similar 
concentration of palmitate, oleate, linoleate and α-linolenate showed varied effect on 
glucose transport and phosphorylation.  These fatty acids contributed to the 
accumulation of LCFA-CoA and other fatty acid metabolites, which interact with 
glucose transport and phosphorylation and decrease the ability of insulin to induce 
glycogen synthesis in vitro.  Other studies in cell culture revealed that exposure to 
saturated fat resulted in the accumulation of DAGs and TAGs, whereas unsaturated fat 
accumulates as intracellular free fatty acids (Gaster et al., 2005).  Others have reported 
that a SAT diet or treating cells with saturated fats is involved in the accumulation of 
fatty acid metabolites including DAGs and ceramides, and interferes in insulin 
stimulated glucose uptake and thereby causing insulin resistance (Maron et al., 1991; 
Parker et al., 1993; Montell et al., 2001). In contrast, PUFA results in the accumulation 
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of IMTGs and free fatty acids and serve a protective function from fatty acid induced 
lipotoxicity by promoting TAG accumulation (Montell et al., 2001; Chavez & 
Summers, 2003; Gaster et al., 2005).  However, a study in rats showed that a diet high 
in polyunsaturated fat reduced TAG levels and improved insulin sensitivity (Jucker et 
al., 1999).  These past investigations strongly suggest that a SAT diet is worse than a 
PUFA diet in causing insulin resistance; however the exact mechanisms behind this are 
not clear.   
 
1.3 Stearoyl-CoA Desaturase (SCD) 1 
1.3.1 Regulation of SCD1 
SCD1 is a 37 kDa protein with a half life of 3-4 hrs (Heinemann & Ozols, 1998) and is 
expressed as different isoforms depending upon the mammalian species.  SCD1 is 
expressed in the liver, adipose tissue (Ntambi et al., 1988), skeletal muscle, brain, 
kidney, spleen, heart, lung, skin (Kaestner et al., 1989), sebocytes and hair follicles 
(Zheng et al., 1999).  SCD1 expression is low in skeletal muscle compared to adipose 
tissue and remains consistent with its low lipogenic activity.  SCD1 expression is 
regulated by various dietary, hormonal and environmental factors.  Dietary factors 
including a high carbohydrate diet (Ntambi et al., 1988; Ntambi, 1992), high plasma 
glucose (Waters & Ntambi, 1994), fructose (Jones et al., 1998) and cholesterol (Kim et 
al., 2002), and hormonal factors such as insulin (Waters & Ntambi, 1994), growth 
hormone (Beswick & Kennelly, 2000) and androsterone (Imai et al., 2001) induce 
SCD1 expression.  Recently, the anti-diabetic drugs PPARα (Peroxisome proliferators 
activated receptors α ) and LXR (Liver X receptors) agonists have been shown to 
increase SCD1 expression (Miller & Ntambi, 1996).  In contrast, it appears that PUFAs 
(Waters & Ntambi, 1994, 1996), conjugated linoleic acid (Lee et al., 1998), thyroid 
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hormone (Waters et al., 1997), leptin (Cohen et al., 2002), glucagon (Lefevre et al., 
1999), tumor necrosis factor-α (Weiner et al., 1991) and sulphur substituted fatty acids 
(Hovik et al., 1997) inhibit SCD1 gene expression.  It is now clear that these dietary and 
hormonal factors influence SCD1 transcription via induction of a sterol regulatory 
element binding protein (SREBP) dependent mechanism (Kersten, 2001; Shimano, 
2001).  It is also believed that SCD1 is not controlled via post-transformational 
modification, although further studies are required to confirm this. 
 
1.3.2 Role of sterol regulatory element binding protein (SREBP) 1c in 
SCD1 expression 
SREBP plays an important role in regulating the expression of SCD1.  SREBPs act as 
lipid sensors that undergo a proteolytic process that serves as a transcription factor for 
fatty acid synthetic genes including SCD1 (Heinemann & Ozols, 1998).  SREBPs 
belong to the group of transcription factors that are attached to endoplasmic reticulum 
(ER) as inactive precursors.  Each precursor is constructed with about 1000 amino acids 
residues capable of three different domain settings to serve as transcription factors.  
Three SREBP isoforms have been identified in the mammalian genome and include 
SREBP-1a, SREBP-1c and SREBP-2.  SREBP-1c is a specific transcription factor of 
SCD1 and many studies in the liver have shown that SREBP-1c plays a critical role in 
SCD1 transcription (Shimomura et al., 1998; Foretz et al., 1999).  Indeed, SREBP-1c 
deletion resulted in diminished expression of the whole class of lipogenic genes, 
including SCD1 (Shimano et al., 1997) whereas LXR ablation resulted in reduced 
expression of SREBP-1, SCD1 and fatty acid synthase suggesting its prominent role in 
lipogenesis (Joseph et al., 2002).  
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1.3.3 Functional role of SCD1 in cell function 
SCD1 is an endoplasmic reticulum bound lipogenic enzyme that catalyses the 
conversion of saturated fats (palmitoyl and stearoyl-CoA) to monounsaturated fats 
(palmitoleoyl and oleoyl-CoA) (Ntambi & Miyazaki, 2004).  Almost all the work 
investigating SCD1 function has been conducted in liver and adipose tissue.  The 
monounsaturated fats acts as substrates for the synthesis of triglycerides, wax esters, 
cholesteryl esters and membrane phospholipids.  The ratio of saturated to 
monounsaturated fats contributes to the membrane phospholipid composition and 
aberrations in the ratio lead to various disease states including diabetes, obesity, 
cardiovascular disease, neurological disease, skin disorders and cancer.  Recent studies 
have provided much evidence regarding the physiological role of SCD1 by examining 
the SCD1 mutation (Zheng et al., 1999) and targeted disrupted models (SCD1-/-) in mice 
(Miyazaki et al., 2001).  In these models, mutations revealed that SCD1 is essential in 
de novo synthesis of different lipids irrespective of the presence of other lipogenic 
enzymes such as DGAT and ACAT.  SCD1 activity is found to be elevated in adipose 
tissues of obese rodents (Cohen et al., 2002); especially in leptin deficient obese mouse 
models (Cohen et al., 2002).  Thus the SCD1 expression has physiological significance 
in normal and disease conditions.  
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Figure 1.6 Schematic representation of biochemical pathway of fatty acid metabolism 
involving stearoyl CoA desaturase 1.  Fatty acid synthase (FAS), stearoyl CoA 
desaturase1 (SCD1), diacylglycerol (DAG). 
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1.3.4 Role of skeletal muscle SCD1 in metabolism 
SCD1 activity in skeletal muscle is known to be positively correlated with body weight 
of human subjects (Jones et al., 1996).  A recent study by Hulver et al. (Hulver et al., 
2005) also demonstrated that SCD1 activity is upregulated in obese subjects, and also 
reported increased production of MUFAs and reduced fatty acid oxidation in primary 
myotubes, indicating that SCD1 expression in obese conditions contributes to abnormal 
lipid metabolism.  Similarly, in mice, SCD1 deficiency in skeletal muscle reduced 
ceramide synthesis via reduced activation of serine palmitoyl transferase and decreasing 
its substrate by CPT1-induced increase of β-oxidation (Dobrzyn et al., 2005).  
 
Another approach used to investigate SCD1 function is via the use of SCD1 specific 
antisense oligonucleotide inhibitors (Jiang et al., 2005a).  Antisense oligonucleotide 
(ASO) treatment resulted in diminished de novo fatty acid synthesis, lipogenic gene 
expression and increased expression of genes involved with energy expenditure in 
adipose tissue.  Whether these treatments have effects in skeletal muscle were not 
reported.  Other factors to influence skeletal muscle SCD1 expression include exercise, 
which increased skeletal muscle SCD1 expression (Ikeda et al., 2002).  The role of 
dietary fatty acids on SCD1 expression and activity in skeletal muscle is unknown. 
Most of the studies investigating the functional importance of SCD1 have utilised a 
recently developed murine knockout (-/-) model. In a series of investigations, Ntambi 
and co-workers assessed different lipogenic and fatty acid β-oxidation gene expression 
in SCD1 (-/-) and SCD1 (+/-) models. SCD1-/- models showed that lipogenic genes 
including SREBP-1, GPAT, and FAS are downregulated whereas, lipid oxidation genes 
including PPARα, ACO, CPT-1, VLCAD are upregulated (Ntambi et al., 2002a) in 
liver.  
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1.3.5 Role of SCD1 in insulin resistance 
The weight of experimental evidence suggests that SCD1 contributes to the 
pathogenesis of obesity and insulin resistance.  SCD1 content is elevated in the livers of 
insulin resistant ob/ob and lipoatrophic mice (Cohen et al., 2002; Asilmaz et al., 2004) 
and in animals rendered insulin resistant by high-fat feeding (Biddinger et al., 2005).  
Moreover, SCD1 null (abJ/ abJ, SCD1-/-) mice (Cohen et al., 2002; Ntambi et al., 2002a) 
and mice treated with SCD1 specific antisense oligonucleotide inhibitors (Jiang et al., 
2005a) exhibit a leaner phenotype and resistance to diet-induced obesity.  SCD1 
deficiency was associated with improved insulin signalling by activating insulin 
receptor tyrosine phosphorylation and down regulating the activity of protein-tyrosine 
phosphatase-1B, which is known to attenuate insulin signalling (Rahman et al., 2003).  
However, the interpretation of SCD1 function in SCD1 knockout mice is confused by 
the findings of increased energy expenditure (Ntambi et al., 2002a; Jiang et al., 2005a) 
and basal thermogenesis (Lee et al., 2004b), and adaptive alterations in metabolic genes.  
In a recent study (Voss et al., 2005), overexpression of SCD1 in myotubes resulted in 
reduced insulin stimulated glucose uptake; however, upon closer inspection it appears 
as though the authors conclusions were incorrect.  In actually, untreated cells became 
less responsive to insulin after palmitate exposure whereas SCD1 overexpressing cells 
showed no such decrease.  This suggests that SCD1 overexpression was in fact 
protective.  Thus, the role of SCD1 in skeletal muscle fatty acid metabolism and insulin 
resistance are poorly described and provides the impetus for the studies completed in 
this thesis.   
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1.4 Aims of thesis 
The primary aims of the thesis were: 
(1)  To examine the effects of different high fat diets on insulin sensitivity, skeletal 
muscle lipid metabolite accumulation, insulin resistance and SCD1 expression. 
(2)  To determine the role of SCD1 on substrate metabolism in fatty acid-induced 
insulin resistance through transient knockdown and overexpression in L6 
myotubes. 
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2.1 Animal experiments 
Twenty four male Sprague-Dawley rats (initial body mass 95-110 g) were obtained 
from Samtako (Bio Korea, Kyoung-Ki, Korea) and housed four per cage in an 
environmentally controlled laboratory (temperature 22±1°C, and relative humidity, 
55±2%) with a 12-hour light-dark cycle (light, 0700 to 1900).  In the week before any 
experimental intervention, animals were given ad libitum access to standard rodent 
chow (Samtako, Bio Korea, Kyoung-Ki, Korea).  Food intake was not determined in 
this study because the PUFA diet was too ‘liquid’ to obtain accurate measures of the 
food remaining in cages.  The Animal Ethics Committee of Korea National Sport 
University approved all procedures performed in this study.  
 
After one week, rats were divided into one of three experimental diet groups.  Control 
rats (CON; n=8) were fed standard rat chow (61.8% carbohydrate, 15.7% fat, 22.5% 
protein expressed as % of total caloric intake).  The other groups consumed high fat 
diets (24.3% carbohydrate; 52.8% fat; 22.9% protein) that consisted primarily of 
saturated fatty acids (SAT; n=8) derived from lard and coconut oil or polyunsaturated 
fatty acids (PUFA; n=8) derived from safflower oil (ICN Biomedicals, CA, USA).  The 
PUFA diet consisted of linoleic acid (18:2; n-6).  Animals, regardless of different 
dietary conditions, were provided with food and water ad libitum throughout the 
experimental period.  Animals were maintained on their diets for eight weeks prior to 
testing.  
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2.1.1 Table of diet composition and energy contents of the diets 
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2.1.2 Oral glucose tolerance test 
Following the six week experimental period, rats were overnight fasted, weighed and 
underwent an oral glucose tolerance test (OGTT).  Glucose (20% w/v solution) was 
administered by oral gavage at a dose of 2.0 g/kg body mass, and blood was obtained 
from a tail vein prior to glucose administration and at 15, 30, 60 and 120 min thereafter.  
At least 2 days after OGTT and after an overnight fast (10 h), rats were anaesthetised by 
intraperitoneal injection of sodium pentobarbital (60 mg/kg body mass) and the vastus 
lateralis muscle was rapidly dissected out, immediately frozen in liquid nitrogen and 
stored at -80oC until analyses.  A blood sample was drawn from the femoral artery and 
rats were sacrificed by heart removal. 
 
2.2 Cell culture  
L6 cells were cultured following aseptic techniques in 75cm² flasks containing growth 
media, which consisted of αMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin (v:v).  The media was replaced daily with pre-warmed media 
(37ºC) until the cells were 60–70% confluent.  Cells were washed twice with pre-
warmed PBS and treated with 4 ml of 0.25% trypsin for 4 min with shaking each 
minute.  Once the cells were completely detached the total number of cells were 
counted then seeded into 6 well plates at 7000 cells per cm².  Cells were grown to 60% 
confluency before transfection. 
 
2.2.1 Short interfering RNA (siRNA) 
RNA interference (RNAi) is a process in which the introduction of double-stranded 
RNA (dsRNA) into the target cell degrades the complementary mRNA and suppresses 
the expression of the target protein (Caplen, 2004).  The RNAi synthesis is a multistep 
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process.  In this process, the RNAase III family member (e.g., Dicer in Drosophila) 
recognizes dsRNA and cleaved it into 21-23 nucleotides of siRNA (Agrawal et al., 
2003).  These siRNAs are integrated into the RNA Induced Silencing Complex (RISC).  
This RISC complex is aimed to the target complementary RNA species which is 
cleaved and results in reduced protein expression.  
 
After reaching 60% confluence, L6 myoblasts were washed with warm PBS and 
trypsinised with 300µl of 0.25% trypsin for 4 min at 37ºC with shaking each minute.  
Cells were allowed to reattach with the addition of 2 ml growth media.  After 16-20 h 
cells were washed with warmed PBS and 1ml DMEM (without serum and antibiotics) 
was added to each well. 
 
Two siRNA sequences of rat SCD1 were tested for their capacity to decrease SCD1 
protein levels in L6 myotubes.  Gene silencing was achieved with equal efficacy with 
the following pairs of 21 bp oligonucleotide sequences (accession number NM139192, 
siRNA ID 58064 and siRNA ID 57973, Ambion, Austin, Texas, USA).  The 
oligonucleotide pairs were annealed and reconstituted in RNAse-free water.  A negative 
control siRNA was also purchased (catalogue number 4613) to account for off-target 
effects.  For transfection, the cell culture media was changed to DMEM and 50 pmol of 
the respective oligonucleotide sequence was added with Lipofectamine 2000 
(Invitrogen) to give a final concentration of 30 nM.  The transfection media was 
removed after 16-20h, cells were washed with PBS and differentiated as described. 
 
2.2.2 Transient transfection procedures 
Hygro-mSCD1/pcDNA3.1 (was a kind gift from Dr.Allan Tall, Division of Molecular 
Medicine, Department of Medicine, Columbia University, New York, USA) spotted 
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onto filter paper was placed in a sterile eppendorf tube with 500 µl of sterile water.  It 
was heated for 10 min at 300C and was freezed until required. The DNA plasmid was 
diluted 1:100 and quantified on a spectrophotometer at 260 nm.  The yield was 
calculated as absorbance at 260 nm X 40 X dilution factor / 1000.  The plasmid was 
introduced into DH5 α (50 µl aliquots) competent cells (E.coli that takes up plasmid) by 
an electroporator (Gene pulser II, Biorad, Australia) with added SOC media without 
antibiotic.  After the electroporation process this plasmid mixture was spread on a 
prepared agar plate and incubated overnight at 37oC.   Depending upon the quantity of 
plasmid required, 2 or 3 colonies of plasmid from the agar plate were taken and seeded 
in the Luria broth (LB) and mixed on an orbital shaker at 37oC for 20 hours at 150 rpm.  
The LB media containing the bacteria was purified and the plasmid was obtained using 
a commercially available kit (Promega Wizard Midi prep Kit).  The DNA yield was 
spectrophotometrically determined and averaged 50 µg/µl.  
 
Cells were transfected using a mixture of DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl sulfate) and DOSPER (1,3-Di-Oleoyloxy-2(6-
Carboxy-spermyl)-propylamide) in filter-sterilised HEPES buffered saline (42mM 
HEPES, 274 mM NaCl,1.4 mM Na2HPO4 , 11 mM dextrose, pH 7.1).  The mixture was 
added to the cells in 1ml α-MEM supplemented with 10% fetal bovine serum.  The 
transfection media was removed after 16-20 h, cells were washed with pre-warmed PBS 
and differentiated as described above. 
 
2.2.3 Determination of DAG and TAG incorporation in L6 myotubes 
 
L6 myoblasts were maintained at 37°C in 5% CO2/95% O2 humidified air in α modified 
essential medium +10% fetal bovine serum (FBS).  Differentiation was induced by 
switching to medium containing 2% FBS when the myoblasts were ~70% confluent. 
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Experimental treatments were started after 2 days, by which time nearly all of the 
myoblasts had fused to form myotubes.  Cells were incubated with 0.5 mM/L palmitate 
(16:0) or 0.5 mM/L linoleate (18:2) conjugated to 2% bovine serum albumin (BSA), or 
2% BSA alone (CON) for 5 h. The media was supplemented with 0.25 mM/L palmitate 
and 14C-palmitate (0.5 µCi/ml) and cells were incubated for a further 2 h.  Incorporation 
of the radiolabelled fatty acid was determined by lysing cells in methanol and extracting 
lipids in chloroform: methanol (2:1). The organic phase containing TAG and DAG was 
removed and dried with nitrogen gas. The lipids were reconstituted, loaded onto silica 
gel plates and the lipid fractions were separated by thin layer chromatography.  The 
bands corresponding to TAG and DAG were visualised under long-wave UV after 
spraying with chlorofluorescein dye (0.02% w/v in ethanol), and bands were scraped for 
liquid scintillation counting (Tri-Carb 2500TR, Packard, Canberra, Australia).  In 
separate experiments, TAG, DAG and ceramide content were determined in cells 
(described below) after 5 h fatty acid treatment.  For determination of 2-deoxy-D-[14C] 
glucose uptake, cells were grown as described and incubated in 0.5 mM fatty acids or 
BSA for 5 h.  Cells were washed with warm phosphate buffered saline (PBS) and 
incubated in MEM without (basal) or with 100 nM/L insulin for 30 min.  The media 
was removed and 2-deoxy-D-[14C] glucose uptake (0.5 µCi/ml, 10 µM/L cold 2-DG) 
was added.  The assay was stopped after 20 min by the addition of ice-cold PBS and 
cells were lysed in 0.3 M NaOH.  Radioactivity was determined by liquid scintillation 
counting. 
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2.3 Analytical procedures 
2.3.1 Measurement of skeletal muscle lipid metabolites 
DAGs and ceramide were extracted and quantified according to the methods of Preiss 
(Preiss et al., 1986).  Ceramide and DAG levels from untreated and palmitate treated L6 
myotubes of skeletal muscle were determined using the DAG kinase method.  This 
involved the extraction and separation of the lipids, the phosphorylation of ceramide 
and DAG by DAG kinase with radioactively labelled ATP (32P), detection using 
radiography and quantification of the products by scintillation counting.  The 
radioactive label incorporated into the products of the DAG kinase reaction is therefore 
proportional to the amount of ceramide and DAG in the treated myotubes.  The 
reactions are as follows: 
     
Ceramide  +  AT32P   ↔  Ceramide-1-32P 
 
DAG   +  AT32P   ↔  Phosphatidic Acid 
 
After palmitate treatment of the myotubes, the media was removed and the myotubes 
were washed twice with warmed phosphate buffered saline (PBS).  These myotubes 
were then lysed with ice-cold 1M NaCl and transferred to clean glass kimble tubes 
where 750 µl of 1:2 chloroform: methanol (v:v) was added and tubes were  mixed.  
Then 250 µl of 1M NaCl and 250 µl chloroform was added and samples were again 
mixed.  The samples were then incubated on ice for 30 min and centrifuged 400 x g for 
20 min (Beckman Coulter Allegra 6R Centrifuge).  The supernatant was removed and 
400 µl of the lower phase was transferred to new kimble tubes.  The lower phase was 
dried under nitrogen before the addition of 400 µl of 2:1 chloroform: methanol (v:v) and 
DAG Kinase 
DAG Kinase 
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vigorous mixing.  Samples were transferred to new glass kimble tubes and 20 µl 
cardiolipin/octylglucoside mix (5 mM cardiolipin, 7.5% octylglucoside (v:v), 1 mM 
DETAPAC, (pH 7.0) was added.  The samples were mixed and incubated at room 
temperature (RT) for 15 min.  To commence the reaction, 100 µl of reaction mixture 
(2X Reaction buffer:  200 mM Imidazole HCl, 200 mM NaCl, 50 mM MgCl2, 4 mM 
EGTA), DAG kinase (Sigma-Aldrich), 20 mM ATP, 20 mM DTT, 0.5 µCi/µL dH2O + 
32P-ATP)) was added to the samples and incubated for 2h at RT.  The reaction was 
stopped with the addition of 4 ml of 2:1 chloroform: methanol (v:v).  The phases were 
separated with 1% HClO4 (v:v), mixed and centrifuged at 400 x g for 2 min.  The upper 
phase was discarded and 2.5 ml of the organic phase was transferred to a new kimble 
tube and dried under nitrogen.  The lipid was reconstituted in 65 µl of 2:1 chloroform: 
methanol (v:v) and 30 µl of sample was spotted onto heat activated thin layer 
chromatography (TLC) silica plates.  The TLC plate was developed in solvent system 
containing chloroform: acetone: methanol: acetic acid: water, 100:40:20:20:10.  The 
TLC plate was dried and placed in a cassette with film on top and exposed overnight.  
The film was developed the next morning and DAG and ceramide bands detected.  The 
corresponding bands on the TLC plate were scraped and added to 5 ml of scintillation 
fluid (StarScint, Perkin Elmer Analytical Sciences).  Radioactivity was determined on 
the 2500 TR Packard Liquid Scintillation Analyser. 
 
2.3.2 Determination of triacylglycerol fatty acid composition 
Freeze-dried muscle (~100 mg) was extracted with chloroform-methanol (2:1 by 
volume) containing 10 mg/L of butylated hydroxytoluene.  After storage of the samples 
overnight at 4oC, each sample was filtered through Whatman paper, rinsed with an 
additional volume of extracting solvent and partitioned against 0.9% NaCl.  This was 
 43 
evaporated under nitrogen gas and the lipids were reconstituted in chloroform.  Samples 
were spotted onto TLC plates and developed in a solvent consisting of petroleum ether: 
diethyl ether: acetic acid (85:15:3 v:v:v) and the TAG fraction was identified against a 
standard (Nu-Chek, 18 5A) and scraped into a vial. Methyl esters of fatty acids of the 
TAG extract were prepared by saponification using 5% H2SO4 in methanol.  The fatty 
acid methyl esters were separated by capillary gas liquid chromatography using a 50m x 
0.32 mm (I.D.) fused silica column bonded phase column (BPX70, SGE, Melbourne, 
Australia) with helium as carrier gas at a flow rate of 43cm/sec.  The column oven was 
maintained at 125oC for 3 min and increased at a rate of 8oC/min to 220oC and this 
temperature was maintained for the duration of the run.  Fatty acids were identified by 
comparison with standard mixtures of fatty acid methyl esters and the results are 
expressed as percent of the total TAG fraction. 
 
2.3.3 SCD1 Activity 
An index of SCD1 activity was calculated as the relative amount of product (16:1) to 
the corresponding substrate (16:0).  
Saturation index / SCD1 activity = [16:1(n7)/16:0) x 100]. 
Palmitic acid (16:0), Palmitoleic acid (16:1). 
 
2.3.4 Blood metabolite and hormone analysis 
Whole blood was obtained from the tail vein and used for blood glucose (Glucocard II, 
KDK, Japan) and lactate determination (Yellow Springs Instruments 1500, Yellow 
Springs, OH, USA) prior to anaesthesia.  Whole blood was transferred to an EDTA-
administered tube, centrifuged (5,000 rpm for 15 min) and the plasma collected.  Free 
fatty acid concentration was determined by an enzymatic colorimetric method (NEFA C 
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test kit, Wako, Japan) and insulin concentration was measured by enzymatic 
immunoassay ELISA kit (Mercodia AB, Uppsala, Sweden).  
 
2.3.5 Fatty acid metabolism  
A palmitate solution consisting of (α minimum essential medium (αMEM), 2% fatty 
acid free bovine serum albumin (BSA) (w: v) and 1 mM palmitate in 100% ethanol was 
prepared.  The palmitate solution was incubated on a roller for 1 h and diluted to the 
desired concentration with αMEM.  Where required, 14C-palmitate (Amersham 
biosciences, Piscataway, NJ, USA) was added to the palmitate media at a final 
concentration of 0.5mM.  1ml of palmitate solution is added to each well and incubated 
for 2 hours.  After that the media is collected to determine fatty acid oxidation by the 
addition of 1ml of the collected media was added to a vial containing 1ml of 1M H2SO4 
and a microcentrifuge tube with 1ml of 1M benzethonium hydroxide.  The liberated 
14CO2 was trapped in the microcentrifuge containing benzethonium hydroxide, and it 
was fixed in a scintillation vial and the radioactivity was counted to calculate the rate of 
fatty acid oxidation.  Palmitate uptake was calculated as the sum of oxidation and 
esterification. 
 
2.3.6 2-Deoxyglucose uptake  
L6 myoblasts were maintained at 37°C in 5% CO2/95% O2 humidified air in α modified 
essential medium (αMEM), +10% fetal bovine serum (FBS).  Differentiation was 
induced by switching to medium containing 2% FBS when the myoblasts were ~70% 
confluent.  Experimental treatments were started after 2 days, by which time nearly all 
of the myoblasts had fused to form myotubes.  Cells were incubated with 0.5 mM/L 
palmitate (16:0) or 0.5 mM/L linoleate (18:2) conjugated to 2% BSA, or 2% BSA alone 
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(CON) for 5 h and TAG, DAG and ceramide content were subsequently determined 
(described above).  For determination of 2-deoxy-D-[14C] glucose uptake, cells were 
grown as described and incubated in 0.5 mM fatty acids or BSA for 5 h.  Cells were 
washed with warm PBS and incubated in α MEM without (basal) or with 100 nM/L 
insulin for 30 min.  The media was removed and 2-deoxy-D-[14C] glucose (0.5 µCi/ml, 
10 µM/L cold 2-DG) was added.  The assay was stopped after 20 min by the addition of 
ice cold PBS and cells were lysed in 0.3 M NaOH.  Radioactivity was determined by 
liquid scintillation counting. 
 
2.3.7 Evaluation of mRNA content by real time-polymerase chain 
reaction (RT-PCR) 
RT-PCR was employed to determine the mRNA expression of the genes of interest.  
Here, the relative abundance of the mRNA of interest in inversely related to the cycle 
number (the point we see an exponential rise in PCR product).  The point at which the 
exponential increase in gene product occurs is called the critical threshold (CT).  We 
then quantified the expression of the gene of interest by employing the comparitive 
delta CT method.  All genes of interest were expressed relative to the house-keeper 
gene, 18S.  
 
Probe and primer design 
The sequences of the primers and probe were as follows: forward primer, 5’-CAC GCC 
GAC CCT CAC AA-3’; reverse primer,5’-TCT TTG ACA GCC GGG TGT TT-3’; 
Taqman probe, 5’-TTC TTC TCT CAC GTG GGT TGG CTG CTT-3’.  Ribosomal 18S 
was used as a constitutive housekeeping control (Applied Biosystems, Foster City CA, 
USA).  Before using PCR technique on SCD1 gene we performed a series of 
experiments to optimise the PCR conditions. 
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Primer optimisation 
We conducted experiments to determine the optimal primer conditions for SCD1. 
Maximum fluorescence and lowest cycle number were considered as optimal primer 
concentration.  To determine the optimal primer concentration 25µl loading volume of 
TaqmanR Universal PCR master mix (1X), 2ng of cDNA, 200nM of SCD1 TaqmanR   
probe, sterile water and SCD1 forward and reverse primers was used in each PCR 
reaction.  The forward and reverse primers at concentrations of 50nM, 300nM, 900nM 
were added in different ratios in each PCR reaction.  
 
Blank samples with no forward and reverse primers were also used as controls.  Each 
reaction was carried out in duplicate and amplified using multiplex comparative critical 
threshold method (Bio-Rad, i Cycler, IQTM, Hercules, CA) with conditions set at 500C 
for 2min, 950C for 10min, followed by 40 cycles of 950C for 15 sec and 600C for 1min. 
In this experiment 300nM forward and 300nM reverse primer concentrations were 
considered as optimal as they resulted in the highest fluorescence at the lowest cycle. 
 
Probe optimisation 
To determine the optimum concentration for TaqmanR probe, experiments were 
conducted at different conditions.  Here also in primer concentration, determination of 
optimum concentration was with maximum fluorescence at lowest cycle number.  Each 
PCR reaction was carried out at a loading volume 25µl including TaqmanR Universal 
PCR master mix (1x), 2ng cDNA, 300nM   reverse primer, 300nM forward primer, 
sterile water and SCD1 TaqmanR probe.  In this experiment the probe was added at 
different concentrations ranging from 50 to 200 nM at 25 nM intervals.  Each reaction 
was carried out in duplicate and amplified using multiplex comparative critical 
threshold method (Bio-Rad, i Cycler IQTM, Hercules, CA) with conditions set at 50oC 
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for 2min, 95oC for 10 min, followed by 40 cycles of 95oC for 15 sec and 60oC for 1 
min.  In this experiment, 100 nM probe concentration was considered as optimal as that 
resulted in the highest fluorescence at the lowest cycle. 
 
cDNA optimisation 
To determine the optimum concentration for cDNA for the PCR reaction, experiments 
were conducted under various conditions.  Here primer concentration determination  
was by maximum fluorescence at lowest cycle number.  Each PCR reaction was carried 
out at a loading volume 25 µl including TaqmanR Universal PCR master mix (1x), 300 
nM reverse primer, 300 nM forward primer, sterile water and 100 nM SCD1 TaqmanR 
probe.  In this experiment cDNA was added at different concentrations ranging from 0 
to 5 µl (2 ng cDNA = 1µg/1µl) at 0.5 µl intervals.  Each reaction was carried out in 
duplicate and amplified using the multiplex comparative critical threshold method (Bio-
Rad i Cycler IQTM, Hercules, CA) with conditions set at 50oC for 2 min, 95oC for 10 
min, followed by 40 cycles of 95oC for 15 sec and 60oC for 1 min.  In this experiment, 1 
µl cDNA concentration was considered as optimal as that resulted in the highest 
fluorescence at lowest cycle. 
 
Ribosomal 18S optimisation  
To optimise the concentration of ribosomal 18S gene experiments were conducted with 
a loading volume of 25µl including TaqmanR Universal PCR master mix (1x), 300 nM   
reverse primer, 300 nM forward primer, sterile water and 100 nM SCD1 TaqmanR 
probe, 200 ng cDNA with ribosomal 18S added at different concentrations ranging from 
50 to 200 nM at 25 nM intervals including one blank without ribosomal 18S.  Each 
reaction was carried out in duplicate and amplified using multiplex comparative critical 
threshold method (Bio-Rad i Cycler IQTM, Hercules, CA) with conditions set at 50oC 
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for 2min, 95oC for 10 min, followed by 40 cycles of 95oC for 15 sec and 60oC for 1min.  
In this experiment 1.25 µl of ribosomal 18S (10ng) was considered as optimal. 
 
Comparison of SCD1 efficiency and 18S amplification 
In multiplex PCR, more than one primer pair was added in each PCR reaction using 
multiplex comparative CT method.  This method was useful in determining reference 
gene ribosomal 18S and SCD1 gene in a single well.  In this multiplex, the presence of 
18S was detected by its ability to emit fluorescence at different wavelength.  To conduct 
the comparative CT PCR, an experiment to determine the efficiency of amplification of 
18S and SCD1 gene was conducted.  To achieve this effect singleplex PCR where 18S 
and SCD1 genes were amplified in separate wells with different cDNA concentrations 
were performed to determine whether the rate of amplification was equal.  This 
experiment resulted in the same efficiencies of 18S and SCD1 amplification over 
different concentrations.  In this reaction 18S primers were controlled to follow the 
conditions of multiplex PCR.  Experiments were then conducted to determine the effect 
of CT values on optimal primer singleplex versus primer limited multiplex 18S.  To 
perform this experiment in singleplex, the primer concentrations were optimised for 
both 18S and SCD1. In multiplex PCR optimised SCD1 with limited 18S primer 
concentrations was used.  This experiment was conducted at different cDNA 
concentrations along with control reactions without cDNA.  Each reaction was 
performed in duplicate.  The CT  values obtained here were compared and observed as 
approximately similar.  This demonstrated that multiplex PCR CT values have no effect 
in comparison with SCD1 singleplex PCR.  
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RNA extraction 
L6 myotubes were treated with Trizol (Life Technologies, Sydney, Australia) for RNA 
isolation.   For muscle samples 1 ml of reagent was used to lyse the cells.  The cells 
were scraped with Trizol and the solution transferred to an eppendorf tube and 200µl 
chloroform was added followed by centrifugation at 17000 x g for 15 min to separate 
the phases.  The upper aqueous phase was transferred to a fresh eppendorf tube, 200µl 
isopropanol was added and the solution was mixed then centrifuged at 12000 x g for 20 
min.  The supernatant was removed and the pellet was washed with 75% ethanol.  The 
RNA pellet was dried and partially dissolved in 10µl (l X RNAse free water). 
 
RNA quantification 
RNA was quantified by spectrophotometry (Hitachi U 2000 spectrophotometer, 
Australia).  1 µl of RNA was diluted in 100 µl of dH2O and the absorbance was 
determined at 260nm.  The absorbance of 1 unit at 260 nm is equal to 40 µg of RNA/ml. 
RNA concentration was calculated accordingly.   
 
Reverse transcription 
RNA samples were reverse transcribed using Taqman Reverse Transcription Reagents 
(Applied Biosystems, Melbourne, Australia).  1 X TaqMan RT Buffer, DEPC Water, 
5.5 mM MgCl, 500 µM dNTP (2.5 mM each), 2.5 µM random hexamer, 0.4 U/µl 
RNase Single  inhibitor, 1.25 U/µl Reverse transcriptase, 0.01 µg/µl of diluted sample 
(for respective reaction). 
 
Taqman real time-polymerase chain reaction 
 The cDNA samples were loaded in duplicate in a 96 well microtitre plate in a total 
volume of 25 µl.  Each reaction contained 10ng cDNA, 12.5 µl iQ super mix 
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(BioRad)(which contains 100 mM KCl, 40 mM Tris-Hcl pH 8.4, 0.4 mM dNTP, 50 
U/µl iTaq DNA polymerase, 6 mM MgCl2, 300 nM TaqMan primer, 100 nM probe, 
0.6µl 18s rRNA control primer).  Probes were designed with the FAM reporter dye on 
the 5’ end and VIC dye to the 3’ end.  18S rRNA was used in the same reaction as a 
constitutively expressed house-keeping gene.  For all PCR experiments, negative 
controls are all constituents without cDNA.  PCR amplification was performed using an 
iCycler iQ Real Time Detection System version 3.021 (BioRad, Australia).  The delta 
(∆) CT method was used to calculate the expression of each sample of the target gene.  
For each sample, a threshold cycle (CT) was obtained for the target gene and the control 
gene (18S r RNA).  The CT for 18s r RNA was subtracted from the CT  of the target 
gene to obtain CT(∆ CT) for each sample.  The difference in the ∆ CT values is 
calculated for each gene of interest between the control and the target gene (Skiba et al., 
2005). 
 
2.3.8 Determination of protein content by western blotting 
Protein extraction 
L6 myotubes or skeletal muscle samples were lysed in ice cold lysis buffer, 
respectively.  Lysis buffer consisted of 20 mM HEPES (pH 7.4), 2 mM EGTA, 50 mM 
β-glycerophosphate, 1 mM dithiothreitol (DTT), 1 mM Na3VO4, 1% TritonX-100, 10% 
glycerol, 5 µl/ml protease inhibitor (Sigma) and 5 µl/ml phosphatase inhibitor (Sigma).  
For skeletal muscle, tissue was freeze dried and homogenized for 10 sec on ice using a 
Polytron homogeniser (Biolab Group, Australia) at full speed.  For cell culture, cells 
were placed on ice and washed with warmed PBS.  Lysis buffer was added and the 
adherent cells were rapidly removed with a plastic plate scraper.  For both tissue and 
culture, the cell solution was transferred into an eppendorf tube and centrifuged at 
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16,000 x g for 20 min.  The supernatant was transferred to an eppendorf tube and 
rapidly frozen in liquid nitrogen for later analysis. 
 
Protein determination  
The supernatant containing cellular protein was diluted 1:50 with water and the protein 
content was determined using the bicinchoninic acid (BCA) method using BSA as a 
standard (Sigma).  The samples and standards were determined in duplicate in a 96 well 
plate using a commercially available kit (MicroBCATMProtein Assay Reagent Kit, 
Quantum Scientific, Australia).  The plate was incubated for 30 min at 55ºC and 
absorbance was determined at 560 nm on a spectrophotometer (Victor3TM 1420, 
Multilabel Counter, Wallac).  The protein content in each well was calculated from the 
linear regression obtained from the standards absorbance reading. 
 
Solubilisation of proteins 
For solubilising the proteins Lamelli’s buffer was prepared.  The 4 X Lamelli’s buffer 
consisted of 40% glycerol (v:v), 8.2%SDS (Sodium Dodecyl Sulphate)(w:v), 0.5 M 
Tris-Hcl(v:v), 1% Bromophenol blue(v:v), adjusted to pH 6.8.  Immediately prior to 
use, 31mg DTT was added to 500µl of Lamelli’s buffer.  Lamelli’s buffer and an 
appropriate volume of water was added to lysates, mixed and heated at 95oC for 5 min. 
Samples were spun at 5,000 x g for 1 min prior to loading. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
Polyacrylamide gels were made in a mini multicasting chamber (Biorad, Melbourne, 
Australia).  Running gels (6-12%) were poured and stacking gel was added.  The 
cassette was placed in an electrophoresis tank filled with running buffer (25 mM Tris 
(pH 8.8), 3 mM SDS, 192 mM glycine).  A 6µg molecular weight protein standard 
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(Precision plus Protein Standards, Biorad) and solubilized protein were loaded into 
individual wells.  The gel was run at 120 V until proteins had passed through the 
stacking gel and was increased to 150 V thereafter. 
 
Transfer and antibody treatment 
The proteins were transferred to a nitrocellulose membrane (Amersham Biosciences, 
Sydney, Australia) and soaked in cold transfer buffer (25 mM Tris, 192 mM glycine, 
20% methanol, v/v) for 5 min before protein transfer.  The transfer was conducted at a 
constant current of 0.06 A per gel for 90 minutes.   After the transfer, the membrane was 
washed with Tris buffered saline with Tween (TBST; 20 mM Tris, 140 mM Nacl, 
0.05% Tween 20, pH 7.6).  The membrane was blocked with 5% skim milk powder 
(w/v) in TBST on a rocker at room temperature for 1 h.  After blocking, the membrane 
was washed with TBST and incubated with primary antibody (1:1000 monoclonal goat 
SCD1 antibody, SantaCruz Biotechnology), 2.5% skim milk, TBST, 0.1% NaN3) 
overnight on a rocker at 4 0C.  The membrane was washed three times with TBST and 
was incubated with secondary antibody (1:2000 antigoat antibody, 2.5% skim milk, 
w:v, and TBST) for 1 h.  The membrane was washed 5 x 5 min with TBST.  The 
immunoreactive bands were detected with 2 ml of chemiluminescence reagent (ECLTM 
Western Blotting Detection Reagents, Amersham Biosciences, England) and exposed 
using the Chemidoc EQ system.  Proteins were quantified using Quantity One software 
version 9 (Biorad Laboratories, Hercules, CA, USA). 
 
2.4 Statistics 
Data are expressed as the mean ± SEM. Statistical analysis were performed by a one-
way or two-way analysis of variance with a Student-Newman-Keuls post hoc test.  
Statistical significance was set at P < 0.05. 
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CHAPTER 3 
SATURATED, BUT NOT POLYUNSATURATED 
FATTY ACIDS, PROMOTE SCD1 EXPRESSION, 
INDUCE LIPID METABOLITE ACCUMULATION 
AND CAUSE INSULIN RESISTANCE 
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3.1 Introduction 
The excessive accumulation of TAG in non-adipose tissue is associated with the 
development of insulin resistance and type 2 diabetes.  Skeletal muscle is a major site 
for insulin-stimulated glucose disposal (Baron et al., 1988a) and the accumulation of 
TAG within lipid droplets in skeletal muscle is positively correlated to the severity of 
insulin resistance (Pan et al., 1997; Forouhi et al., 1999; Krssak et al., 1999).  However, 
insulin sensitivity and IMTG increase after endurance exercise training (Goodpaster et 
al., 2001a; Helge et al., 2001; Bruce et al., 2004) and TAG storage protects chinese 
hamster ovary cells from lipotoxicity,  indicating that IMTG per se does not cause 
insulin resistance but may be a proxy for other lipid metabolites that directly interfere 
with insulin signalling.  Indeed, skeletal muscle insulin resistance is mediated by 
intramyocellular accumulation of fatty acyl-CoA metabolites, such as DAGs and 
ceramides, which are elevated in insulin resistant states (Qu et al., 1999b, a; Yu et al., 
2002; Adams et al., 2004; Lessard et al., 2004) and directly interfere with insulin signal 
transduction (Kanety et al., 1996; Schmitz-Peiffer et al., 1999; Yu et al., 2002; Chavez 
et al., 2003b; Stratford et al., 2004). 
 
Whilst increased availability of fatty acids has been linked to skeletal muscle insulin 
resistance (Bachmann et al., 2001; Boden et al., 2001), it appears that the type of fatty 
acid is also critical.  Epidemiological evidence suggests that the consumption of a 
Western diet that is high in saturated fats closely correlates with the development of 
insulin resistance in humans (Maron et al., 1991; Parker et al., 1993).  Direct 
examination in muscle cells in vitro indicates that saturated fatty acids cause insulin 
resistance whereas unsaturated fatty acids exert a protective effect, or even improve 
insulin sensitivity (Montell et al., 2001; Chavez et al., 2003b). 
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Saturated fats are less readily oxidised (Leyton et al., 1987; Gaster et al., 2005), and 
accumulate as DAG and ceramide in vitro, whereas mono- and polyunsaturated fats 
accumulate as IMTG or free fatty acids (Schmitz-Peiffer et al., 1999; Montell et al., 
2001; Gaster et al., 2005), thus providing a link between fatty acid subtype and insulin 
resistance.  Numerous dietary studies in rodents and humans indicate that saturated fat 
significantly worsens insulin resistance, while monounsaturated and polyunsaturated 
fatty acids have a less pronounced effect, or even improve insulin sensitivity (Riccardi 
et al., 2004).  The biochemical and molecular processes linking saturated fats to insulin 
resistance remain unresolved, but may relate to altered membrane phospholipid fatty 
acid composition and membrane fluidity and stability (Storlien et al., 1991), changes in 
lipogenic gene transcription (Clarke, 2004), the type of fatty acids within TAG (Matsui 
et al., 1997; Andersson et al., 2002) and direct interference with insulin signalling 
(Kanety et al., 1996; Schmitz-Peiffer et al., 1999; Yu et al., 2002; Chavez et al., 2003b; 
Stratford et al., 2004).  Lipid metabolites that interfere with insulin signal transduction 
accumulate in tissues of insulin resistant animals (Turinsky et al., 1990; Schmitz-Peiffer 
et al., 1997; Qu et al., 1999a; Yu et al., 2002; Lessard et al., 2004) however, the effects 
of markedly altering the types of dietary fatty acids on the accumulation of these lipid 
metabolites in whole animals are unknown.  
 
The primary aim of this study was to examine the role of diets rich in either saturated or 
polyunsaturated fatty acids on skeletal muscle fatty acid metabolite accumulation and 
whole body insulin sensitivity.  It was hypothesised that a diet high in saturated fatty 
acids would increase the contents of skeletal muscle DAG and ceramide and induce 
insulin resistance, whereas a diet high in polyunsaturated fatty acids would not affect 
DAG and ceramide contents or impact upon insulin sensitivity.  To confirm the 
biochemical responses to fatty acids, independent of potential changes in metabolic or 
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hormonal fluxes, we also incubated rat L6 myotubes, an in vitro skeletal muscle model, 
with saturated and unsaturated fatty acids and hypothesised that the in vivo effects 
would persist in vitro. 
 
SCD 1 is an endoplasmic reticulum bound enzyme that converts saturated fatty acids 
(primarily 16:0; 18:0) to monounsaturated fatty acids.  Global SCD1 deficiency 
produces a lean, obesity-resistant, insulin sensitive phenotype (Ntambi et al., 2002a); 
however, preventing the ability to desaturate fatty acids should lead to insulin resistance 
because saturated fats accumulate as DAG and ceramide.  While polyunsaturated fatty 
acids reduce and saturated fatty acids increase SCD1 expression in liver (Ntambi, 
1999); the role of dietary fatty acids on SCD1 expression and activity in skeletal muscle 
is unknown, despite the importance of skeletal muscle in fuel metabolism and insulin 
resistance.  Accordingly, the second aim of this study was to investigate the role of 
dietary fatty acids on skeletal muscle SCD1 gene and protein expression in vivo. 
 
3.2 Experimental design 
            The animal experiments in this study were conducted by Dr. Jong Sam Lee (Eulji 
University, South Korea) and were approved by the Animal Ethics Committee of Korea 
National Sports University.  Male Sprague-Dawley rats (Samtako, Biokorea, Kyoungki, 
South Korea) were obtained and maintained as described (p.35) and grouped as control, 
SAT and PUFA diet treated groups.  After 8 weeks of diet treatment, animals were 
fasted overnight and an OGTT was conducted.  Two days later, rats were overnight 
fasted and anaesthetised.  Muscle and fasting blood samples were obtained.  The 
homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated 
from blood samples to calculate the fasting blood glucose and insulin levels (fasting 
insulin (pM/l) x fasting glucose (mM/l)/135).  The muscle samples were immediately 
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frozen in liquid nitrogen.  Muscle TAG, DAG and ceramide content were assessed, as 
were the TAG fatty acid subtypes using gas chromatography.  SCD1 mRNA, protein 
and activity were also assessed.  In separate experiments, the effects of fatty acids were 
assessed in L6 myotubes.  Myotube TAG, DAG and ceramide accumulation and insulin 
stimulated glucose disposal were determined (for procedures refer to general methods). 
 
3.3 Results 
Animal characteristics and glucose tolerance  
Animal weights were not different between groups after 8 weeks diet (CON, 391 ± 9g; 
SAT, 409 ± 7g; PUFA 380 ± 4 g).  Both high fat diets increased plasma free fatty acids 
by ~30% but were without effect on fasting blood glucose (Table 3.1).  Fasting plasma 
insulin was increased in animals fed SAT compared with CON fed animals, and 
reduced in animals fed PUFA (Table 3.1).  The HOMA-IR index was increased in SAT 
and decreased in PUFA compared with CON (Figure 3.1A).  These data indicate that 
SAT rats were insulin resistant and that insulin sensitivity was improved in PUFA rats.  
The glucose area under the curve was not different between groups (Figure 3.1B); 
however, plasma insulin levels were elevated in SAT compared with CON, indicating 
insulin resistance in these animals (Figure 3.1C).  Conversely, plasma insulin levels 
were decreased in PUFA compared with CON indicating improved insulin sensitivity 
(Figure 3.1C). 
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Table 3.1 Body mass and fasting plasma metabolites in rats fed a chow diet (CON) 
or high-fat diet consisting of either saturated (SAT) or polyunsaturated (PUFA) 
fatty acids. 
 
 CON SAT PUFA 
Body mass (g) 391 ± 9 409 ± 7 380 ± 4 
FFA (µM/L) 354 ± 29 460 ± 23* 448 ± 25* 
Glucose (mM/L) 3.99 ± 0.16 4.61 ± 0.15 4.26 ± 0.10 
Insulin (pM/L) 27 ± 5 76 ± 24* 13 ± 3*† 
 
Values are means ± SEM, n=8. * different from CON, † different from SAT, P<0.05. 
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Figure 3.1 Effect of dietary fatty acid subtype on insulin sensitivity in rats. 
(A) The homeostasis model assessment of insulin resistance (HOMA-IR) index was 
calculated from fasting blood glucose and insulin levels.  HOMA-IR = (fasting glucose 
x fasting insulin)/22.5, where glucose is expressed as mM/L and insulin µU/L.  In 
separate experiments, overnight fasted rats were provided with an oral glucose load and 
blood samples were taken at regular intervals over 120 min.  (B) Glucose area under the 
curve and (C) plasma insulin were determined from tail bleeds.  Values are means ± 
SEM, n=8. * different from CON, † different from PUFA, P<0.05. 
 A
 B
 C
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Skeletal muscle lipid content is influenced by dietary content 
Lipids were assessed in skeletal muscle after an 8 h fast.  Skeletal muscle TAG was 
increased in SAT and PUFA compared with CON, and PUFA TAG content tended 
(P=0.08) to be greater than SAT (Figure 3.2A).  Skeletal muscle DAG content was 
increased in SAT and PUFA compared with CON (Figure 3.2B).  DAG content was 
greater in SAT vs PUFA. Ceramide content in rodent muscles was variable and was not 
affected by dietary content (Figure 3.2C).  
 
Effect of dietary fatty acid composition on skeletal muscle triacylglycerol fatty acids 
Dietary fatty acid composition exerted a profound effect on the fatty acid profile in 
skeletal muscle TAG.  SAT increased the proportion of saturated fatty acids and 
decreased unsaturated fatty acids within TAG compared with CON (Figure3.3A).  The 
elevation in saturated fats with SAT could be attributed to increases in 12:0, 14:0 and 
18:0 (Figure 3.3B).  Interestingly, 18:1 was markedly elevated and 18:2 decreased in 
SAT versus CON.  PUFA increased the percentage of unsaturated fats in TAG, which 
was largely due to increased 18:2.  PUFA also decreased the proportion of all saturated 
fatty acid in TAG compared with CON and SAT (Figure 3.3B).  The proportion of 
saturated fatty acids was 32, 42 and 17% for CON, SAT and PUFA, respectively. 
 
SCD1 is increased by a saturated fatty acid diet 
SCD1 mRNA was unaffected by PUFA and tended (P=0.11) to increase with SAT 
compared to CON (Figure 3.4A).  We examined SCD1 protein expression by Western 
blot and report increased SCD1 in SAT compared with CON and PUFA (Figure 3.4C).  
An index of SCD1 enzyme activity, which was calculated as the relative amount of 
product (16:1) to the corresponding substrate (16:0), was increased (P<0.05) in SAT 
compared with CON and was reduced (P<0.05) in PUFA (Figure 3.4D).  The difference 
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in SCD1 activity depending upon various diets indicated that SCD1 expression 
increases with SAT compared to other diets.  
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Figure 3.2 Effect of dietary fatty acid subtype on muscle lipid metabolites.  Overnight 
fasted rats were sacrificed and muscle triglyceride (A), diacyglycerol (B) and ceramide 
(C) were determined.  Values are means ± SEM, n=8. * vs CON, † vs SAT (P<0.05). 
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Figure 3.3 Effect of dietary fatty acid subtype on skeletal muscle triacylglycerol fatty 
acids.  Overnight fasted rats were sacrificed, muscle triglyceride were extracted and 
analysed for fatty acid composition by gas chromatography.  (A) Percent saturated and 
unsaturated fatty acids within triacylglycerols (TAGs), (B) fatty acid profile within 
triacylglycerol (TAG). Values are means ± SEM, n=8. * vs CON ( P<0.05).  
 A
B
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Figure 3.4 Effect of dietary fatty acid subtype on SCD1 expression.  Muscle from 
overnight fasted rats was rapidly dissected and examined for SCD1 mRNA (A) and 
SCD1 protein (C).  A representative immunoblot is shown in (B).  SCD1 activity index 
(D). Values are means ± SEM, n=8. * vs CON, † vs PUFA (P<0.05). 
A
B
C
D
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Effect of palmitate and linoleate on fatty acid metabolite content and glucose uptake 
in L6 myotubes 
To enable biochemical studies to be conducted in the absence of possible confounding 
factors, such as alterations in circulating metabolites and hormones, we performed 
experiments in L6 myotubes.  While the metabolic action of these cells to insulin is 
blunted and direct comparisons with in vivo studies should be interpreted with caution, 
L6 myotubes nevertheless possess the proteins required for fatty acid and glucose 
uptake and metabolism.  Glucose uptake was determined in L6 myotubes after 5 h 
treatment with 0.5 mM palmitate (saturated) or linoleate (polyunsaturated) fatty acids. 
Palmitate decreased insulin stimulated glucose uptake, whereas linoleate pre-treatment 
did not affect glucose uptake (Figure 3.5A).  The addition of palmitate to culture media 
resulted in significant DAG (5-fold) and ceramide (2-fold) accumulation (Figure 3.5 C-
D).  TAG content determined by fluorometric analysis after 5 h incubation revealed a 
small increase with palmitate (Figure 3.5B).  TAG was increased by linoleate treatment 
(Figure 3.5B), whereas DAG and ceramide content were unchanged (Figure 3.5E-F). 
These data indicate that palmitate-induced ceramide and DAG accumulation are 
associated with insulin resistance in skeletal muscle cell culture (Schmitz-Peiffer et al., 
1999; Montell et al., 2001; Chavez et al., 2003a).  They also indicate that linoleate 
promotes synthesis of TAG and does not affect insulin stimulated glucose uptake. 
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Figure 3.5 Lipid storage and glucose uptake in L6 myotubes after 5 h treatment with 
palmitate or linoleate.  (A) 2-deoxyglucose uptake with or without insulin.  (B) 14C-
palmitate incorporation into triacylglycerol (TAG) and (C) diacylglycerol (DAG).  (D) 
L6 myotube triacylglycerol. (E) diacylglycerol and (F) ceramide content.  Values 
represent 2 independent experiments, n=4 per experiment. * versus CON, † versus 
PUFA (P<0.05).  
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3.4 Discussion 
The present study demonstrates that a diet high in SAT induces muscle DAG 
accumulation and saturation of the TAG pool, and is associated with insulin resistance.  
Conversely, animals fed a diet high in PUFA retained insulin sensitivity despite small 
increases in muscle DAG, which may result from enhanced TAG storage.  Thus, fatty 
acid oversupply per se is not the major determinant of fat-induced insulin resistance, but 
rather dietary fat composition (Storlien et al., 1991; Storlien et al., 2001). 
 
An important caveat of the present study relates to the interpretation of insulin 
resistance.  The OGTT and HOMA assessments do not allow for assessment of tissue 
specific effects on insulin-stimulated glucose uptake.  While skeletal muscle accounts 
for >80% of insulin mediated glucose disposal (Baron et al., 1988a), and is likely to 
represent events occurring at the whole body level, it is not certain that the observed 
whole body changes are due to altered skeletal muscle function.  In this regard, it 
appears that glucose intolerance may only become apparent when insulin resistance 
occurs in numerous tissues (Yu et al., 2002).  Thus, the present data relating to insulin 
resistance should be interpreted with these considerations in mind. 
 
DAGs and ceramides antagonise insulin signalling in vitro and this is the first study to 
directly examine the effects of dietary fatty acid composition on the accumulation of 
these lipid metabolites in vivo.  DAGs are increased in fatty acid-induced insulin 
resistance (Yu et al., 2002) and are proposed to interfere with insulin signalling via 
novel PKC activation (Yu et al., 2002).  In this study, DAG was markedly elevated in 
SAT and coincided with insulin resistance,  observations that are consistent with the 
current and previous studies in muscle cell culture that ascribe a direct role for 
saturated, but not unsaturated fatty acids, in this process (Cazzolli et al., 2001; Montell 
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et al., 2001; Chavez et al., 2003b; Gaster et al., 2005).  However, the in vivo finding 
that DAGs were moderately elevated in PUFA rats, where insulin action was improved, 
indicates that total DAG accumulation may not be essential for insulin resistance and 
that other factors such as a critical threshold of intracellular DAG, cellular localization 
of DAG or the molecular DAG species may be important mediators of insulin 
resistance.  Collectively, these data indicate that an abundance of dietary SAT induces 
insulin resistance, possibly via a marked increase in DAG content, whereas smaller 
increases in DAG were not associated with insulin resistance in animals fed an 
isocaloric diet rich in polyunsaturated fatty acids. 
 
Ceramide is a second messenger in the sphingomyelin signalling pathway and is 
produced via the hydrolysis of sphingomyelin and from de novo synthesis (palmitoyl-
CoA and serine).  Ceramides antagonise insulin signalling (Turinsky et al., 1990; 
Schmitz-Peiffer et al., 1999; Simoneau et al., 1999; Chavez et al., 2003b) and ceramide 
accumulation correlates with the development of skeletal muscle insulin resistance in 
vivo (Adams et al., 2004; Straczkowski et al., 2004).  In contrast with the original 
hypothesis, dietary fatty acid composition did not affect muscle ceramide content.  This 
was unexpected because long chain saturated fatty acids are thought to exclusively act 
as the substrate for ceramide de novo synthesis (Summers & Nelson, 2005); however, a 
recent study that infused a lipid emulsion primarily composed of linoleate (18:2) 
induced ceramide generation and insulin resistance in humans (Straczkowski et al., 
2004).  A dissociation between ceramide content and insulin sensitivity has been 
observed previously (Itani et al., 2002; Yu et al., 2002; Lessard et al., 2004) and, 
consistent with the present findings, indicates that ceramides may not induce insulin 
resistance in vivo. 
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IMTG content positively correlates with insulin resistance (Pan et al., 1997; Forouhi et 
al., 1999; Krssak et al., 1999), which has led to the assumption that excess IMTG 
storage is undesirable.  However in some circumstances, such as after endurance 
exercise training, increased TAG is associated with enhanced insulin sensitivity 
(Goodpaster et al., 2001a; Helge et al., 2001; Bruce et al., 2004; Straczkowski et al., 
2004).  In the present study, IMTG was increased in rats fed a SAT, and to a greater 
extent, in rats on the PUFA diet. These data are consistent with the studies conducted in 
L6 myotubes demonstrating increases in IMTG with linoleate compared with palmitate 
treatment. Unsaturated fats promote TAG accumulation in various cell types (eg: 
cardiac, pancreatic, Chinese hamster ovary cells) see (Listenberger et al., 2003)  and 
this and previous experiments in skeletal muscle culture (Montell et al., 2001) have 
demonstrated increased TAG storage after incubation with unsaturated fats.  Thus, 
unsaturated fatty acids may protect cells from “lipotoxicity” by promoting uptake of 
fatty acids into an inert triglyceride lipid pool, rather than bioactive lipids such as DAGs 
and ceramides (Listenberger et al., 2003).  The observations in PUFA rats of elevated 
muscle TAG and reduced DAG content lower basal plasma insulin and enhanced 
insulin sensitivity compared with SAT supports this possibility.  The reasons for IMTG 
accumulation was not addressed in this study but may relate to the preference of DGAT 
(converts DAG to TAG) for unsaturated rather than saturated fatty acids  (Coleman & 
Bell, 1976; Sauro & Strickland, 1990). 
 
The fatty acid profile of different body tissues at least partially reflects the fatty acid 
composition of the diet.  The fatty acid profile of TAG was compared between groups 
in this study.  Eight weeks SAT diet increased the degree of saturation within skeletal 
muscle TAG, which was due to increases in short (12:0, 14:0) and long (18:0) chain 
fatty acids.  It is not known whether an increase in TAG saturation contributes to insulin 
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resistance.  It is possible that the excess stearate (18:0) within this pool is hydrolysed 
and provides a substrate for DAG and ceramide production, thereby affecting insulin 
signalling.  In contrast with SAT, PUFA increased the degree of unsaturation within 
IMTG, which was primarily due to increased linoleate (18:2).  Increased unsaturation of 
the muscle membrane fatty acids is associated with improved insulin sensitivity 
(Storlien et al., 1991) and the lipid-lowering agent, bezafibrate, reduces the saturation in 
muscle TAGs and improves insulin sensitivity (Matsui et al., 1997).  The greater degree 
of desaturation in TAG in this study is associated with improved insulin sensitivity, and 
conversely, an increase in saturation correlates with insulin resistance. 
 
 SCD1 is an endoplasmic reticulum bound enzyme that converts SATs to 
monounsaturated fatty acids.  The current understanding of the biological role of SCD1 
derives from studies in liver and others conducted in SCD1 null (abJ/ abJ, SCD1-/-) 
(Cohen et al., 2002) mice (Cohen et al., 2002; Ntambi et al., 2002a) and mice treated 
with SCD1-specific antisense oligonucleotide inhibitors (Jiang et al., 2005a).   Although 
global knockout studies demonstrate SCD1 deficiency to induce a leaner phenotype and 
resistance to diet-induced obesity (Cohen et al., 2002; Ntambi et al., 2002a), the 
interpretation of SCD1 function is confused by the finding of increased energy 
expenditure (Cohen et al., 2002; Ntambi et al., 2002a) and basal thermogenesis (Lee et 
al., 2004b) in these animals.  Moreover, there is very limited data describing SCD1 
regulation in skeletal muscle.  In the present study, skeletal muscle SCD1 gene and 
protein expression was examined in response to various diets.  SCD1 was not different 
between chow-fed and polyunsaturated fat-fed rats, which is not consistent with the 
findings in liver that polyunsaturated fatty acids oppose the induction of SREBP-1c, and 
inhibit SCD1 gene expression (Waters & Ntambi, 1996; Clarke, 2004).  In contrast, 
SCD1 gene and protein expression were elevated in insulin resistant SAT rats.  These 
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results show an increase in DAG with a concomitant increase in SCD1, suggesting a 
possible causative role of SCD1 in DAG accumulation and insulin resistance.  
However, SCD1 desaturases fatty acids and those fatty acids are preferentially oxidised 
or stored as TAGs.  It is possible that the SCD1 increase occurs in an attempt to reduce 
the increase in saturated fat and DAGs in skeletal muscle.  However, the findings of 
increased SCD1 and insulin resistance in SAT and decreased SCD1 and insulin 
sensitisation in PUFA could be interpreted to mean that SCD1 causes insulin resistance. 
Studies that directly test this hypothesis warrant further investigation.  
 
Chronic high fat feeding induces insulin resistance in rodents, however, the role of 
specific dietary fats is not well characterised.  Previous reports indicate that insulin 
resistance (Storlien et al., 1991; Jucker et al., 1999) or glucose intolerance (Marotta et 
al., 2004) occurs in rats fed a diet high in n-6 PUFAs, whereas rats fed diets high in n-3 
and with low n-6: n-3 ratios maintain normal insulin sensitivity.  In this study, an ~20% 
improvement in HOMA-IR in rats fed a PUFA diet consisting mainly of n-6 fatty acids 
(n-6:n-3 PUFA of >75:1), an effect observed previously in type 2 diabetes patients 
(Heine et al., 1989).  The discrepancies between this and previous rodent studies 
(Storlien et al., 1991; Jucker et al., 1999; Marotta et al., 2004), whilst difficult to 
pinpoint, may be due to the duration of treatment (8 weeks in the present study vs 3-4 
weeks).  With respect to the time course effects, PUFAs upregulate genes involved in 
fat oxidation and decrease genes involved in lipid synthesis / storage (Sampath & 
Ntambi, 2005).  Although the transcriptional response is rapid, the time required for a 
phenotype change may take weeks to manifest and thus explain the observed differences 
between studies.  A more likely explanation is that the chow-fed animals were mildly 
insulin resistant.  These animals gained weight at a similar rate to the PUFAs suggesting 
increased food intake.  It is also possible that the small amount of saturated fats in the 
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chow diet (~10% of total calories) resulted in slight insulin resistance in the controls.  
These possibilities remain to be determined. Another possibility is that the animals in 
the PUFA group may not have accumulated as much body fat as the SAT group due to 
the liquid nature of the diet.  Unfortunately, measures of adiposity and food intake were 
not assessed in this study.  Despite these differences, it appears that an n-6 PUFA diet is 
more desirable than a SAT diet, but that n-3 PUFA substitution for n-6 is advantageous 
for insulin action.  Thus, whilst a diet supplemented with n-3 PUFAs enhances insulin 
action (Preiss et al., 1986; Storlien et al., 1991; Storlien et al., 2001), our data suggest 
that a diet rich in n-6 PUFAs is not detrimental to insulin action as previously described 
and may even result in modest improvements in insulin action.   
 
In conclusion, the results of the present study demonstrate that a diet high in saturated 
fatty acids induces insulin resistance whereas polyunsaturated fatty acids modestly 
enhance insulin sensitivity.  The insulin resistance in the SAT rich diet was associated 
with elevated DAG content and increased saturation of muscle TAG.  These effects 
were partially ameliorated with polyunsaturated fatty acids, possibly via increased 
incorporation into TAG. 
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4.1 Introduction 
 
As mentioned previously, skeletal muscle is an important tissue for insulin-mediated 
glucose uptake and lipid accumulation in skeletal muscle is associated with defective 
insulin signalling, reduced glucose uptake, resulting in insulin resistance and type 2 
diabetes (McGarry, 2002; Unger, 2002; Eckel et al., 2005).  Indeed, in the previous 
study it was shown that saturated fatty acids induce insulin resistance in rats and L6 
myotubes (Figure 3.1). 
 
SCD1 is expressed in various tissues such as adipose tissue, liver and skeletal muscle is 
considered as critical protein in the regulation of insulin action in skeletal muscle. The 
amount and distribution of saturated and unsaturated FAs effects many cellular 
processes including phospholipid composition and membrane fluidity, generation of 
second messengers in signalling cascades, metabolic fuel storage in the form of TAGs, 
cellular differentiation and apoptosis (Listenberger et al., 2003; Busch et al., 2005; 
Scaglia & Igal, 2005). With reference to insulin resistance, recent studies have indicated 
that exposure of skeletal muscle to excess saturated FA results in the generation of the 
fatty acyl-CoA metabolites, DAG and ceramide, that directly interfere with insulin 
signal transduction (Schmitz-Peiffer et al., 1999; Montell et al., 2001; Yu et al., 2002; 
Chavez et al., 2003a; Chavez & Summers, 2003).  Thus, inhibiting SCD1 function 
would be expected to result in the accumulation of fatty acid metabolites that are 
deleterious to insulin signalling and accordingly, the development of FA-induced 
insulin resistance. 
 
Paradoxically, the weight of experimental evidence suggests that SCD1 contributes to 
the pathogenesis of obesity and insulin resistance.  SCD1 content is elevated in the 
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livers of insulin resistant ob/ob and lipoatrophic mice (Cohen et al., 2002; Asilmaz et 
al., 2004) and in animals rendered insulin resistant by high-fat feeding (Biddinger et al., 
2005).  Moreover, SCD1 null (abJ/ abJ, SCD1-/-) mice (Cohen et al., 2002; Ntambi et al., 
2002b) and mice treated with SCD1-specific antisense oligonucleotide inhibitors (Jiang 
et al., 2005b) exhibit a leaner phenotype and resistance to diet-induced obesity (Cohen 
et al., 2002; Ntambi et al., 2002b).  However, the interpretation of SCD1 function in 
these studies is confused by the findings of increased energy expenditure (Ntambi et al., 
2002b; Jiang et al., 2005b) and basal thermogenesis (Lee et al., 2004a), and adaptive 
alterations in metabolic genes.   
 
Skeletal muscle is an important tissue for fat metabolism (van Hall et al., 2002) and 
insulin-stimulated glucose disposal (Baron et al., 1988b), and is accordingly a pivotal 
tissue for energy homeostasis and insulin resistance.  Currently, the biological role of 
skeletal muscle SCD1 in these processes remains poorly understood.  A recent study 
indicated that SCD1 was elevated in skeletal muscle of obese individuals and 
contributed to a decrease in fatty acid oxidation and increased TAG esterification 
(Hulver et al., 2005).  It is unlikely that SCD1 contributes to skeletal muscle insulin 
resistance via this pathway since TAG turnover is relatively slow (Sacchetti et al., 2002) 
and increased IMTG actually correlates with enhanced insulin sensitivity (Goodpaster et 
al., 2001b).  Accordingly, we directly examined the role of SCD1 on fatty acid 
metabolism and insulin resistance in L6 myotubes, an in vitro skeletal muscle model.  
With the use of transient knockdown and overexpression models, we demonstrate that 
SCD1 is required for normal cell function and that increases in SCD1 content protects 
muscle cells from FA-induced insulin resistance. 
 
 76 
4.2 Experimental design 
For animal experiments eight-week old male C57Bl/6J mice (n=12) and four-week old 
male Wistar rats (n=12) were purchased from Monash Animal Sciences.  Male db/db 
mice were a kind gift from Dr. Greg Tesch (Monash University, Victoria, Australia).  
Mice were fed either chow (4% calories from fat) or high fat diets (53% fat) and were 
provided with food and water ad libitum for ten weeks.  Overnight fasted animals were 
anaesthetised by intraperitoneal injection of sodium pentobarbital (60 mg/kg body 
mass) and the gastronemius muscle was rapidly dissected out, immediately frozen in 
liquid nitrogen and stored at -80oC until analyses.  Animals were sacrificed by lethal 
injection of sodium pentobarbital.  All experimental procedures were approved by the 
RMIT Animal Ethics Committee. 
 
L6 myoblasts were used in all experiments involving SCD1 knockdown and 
overexpression.  Cell culture techniques were used as described in the general methods 
(p.37).  L6 myoblasts were grown to 50-60% confluence then treated with siRNA or 
cDNA for 16-20 hrs (p.37-39).  After the differentiation, myotubes were subjected to 
different experiments.  SCD1 mRNA was evaluated by using RT-PCR and protein 
content by western blot.  Fatty acid oxidation, palmitate uptake, lipid metabolite 
accumulation and glucose uptake experiments were conducted separately for 
knockdown and overexpression models. 
 
4.3 Results 
SCD1 expression is upregulated in the skeletal muscle of obese rodents 
Previous studies in liver indicate that SCD1 expression is increased in obese and/or 
insulin resistant animals (Biddinger et al., 2005).  The effects of high-fat feeding were 
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first determined on SCD1 expression in skeletal muscle.  SCD1 protein expression was 
markedly elevated in skeletal muscle of mice (C57Bl/6J) and rats (Wistar) made obese 
by high fat diets (53% fat) provided with water (Figure 4.1A).  Densitometry revealed 
that SCD1 expression was elevated by ~35% after high fat feeding (Figure 4.1B).  We 
next examined the expression of SCD1 in the skeletal muscle of another rodent model 
of obesity/insulin resistance, the db/db mouse.  SCD1 expression was low in muscle 
extracts of db/+ mice, whereas db/db mice displayed a marked increase in SCD1 
expression (Figure 4.1 A-B).  These results demonstrate that skeletal muscle SCD1 
protein content is increased in obese, insulin resistant animals. 
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Figure 4.1 In vivo expression of SCD1 in skeletal muscle of lean and obese rodents.  
(A)Lysates were prepared from skeletal muscles of rodents fed a chow or high fat diet 
(HFD) for 10 weeks or from lean (+/-) or obese (+/+) db/db mice.  60 µg of protein was 
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot 
analysis.  (B) Quantification of western blots (n=4). * different from lean. 
 
 
 
CHOW     HFD
Species: C57Bl/6
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SCD1 knockdown affects fatty acid metabolism in L6 myotubes 
SCD1 protein content in control siRNA treated cells was not different from native L6 
myotubes, whereas SCD1 siRNA reduced SCD1 protein by 40% (Figure 4.2A).  There 
were no differences between native L6 and control siRNA treated cells for SCD1 
protein or any metabolic parameter reported herein (therefore these data are not 
presented).  Palmitate uptake was higher (1.2-fold) in SCD1 siRNA than control cells 
(Figure 4.2C).  Fatty acid oxidation was measured as the sum of 3H released into the 
incubating media and the accumulation of ASM (acid soluble media or partially 
oxidised fatty acids).  Fatty acid oxidation was not different between treatments (Figure 
4.2D), Fatty acid incorporation into TAG was not different between treatments (Figure 
4.2E), whereas SCD1 knockdown resulted in a 2-fold increase in palmitate 
incorporation into DAG (Figure 4.2 F).  
 
The cellular content of DAG and ceramide, fatty acid metabolites known to directly 
interfere with insulin signal transduction (Schmitz-Peiffer et al., 1999; Montell et al., 
2001; Chavez et al., 2003b) was examined.  When cells were grown in FA-free media, 
SCD1 siRNA resulted in a 2- and 3-fold increase in cellular ceramide and DAG, 
respectively, compared with control siRNA (Figure 4.3A-B). When cells were exposed 
to exogenous palmitate, ceramide and DAG content were increased above basal levels 
in both control and SCD1 siRNA cells.  Ceramide content remained higher in SCD1 
siRNA (Figure 4.3A), whereas DAG content was not different between treatments 
(Figure 4.3B).  Taken together, these data demonstrate that reduced SCD1 protein in 
muscle cells results in increased sarcolemmal uptake of fatty acids that are more readily 
incorporated into lipid metabolites that are known to negatively impact on insulin 
signalling. 
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Figure 4.2 SCD1 siRNA moderately reduces fatty acid oxidation and increases the 
incorporation of fatty acids into diacylglycerol (DAG). (A) SCD1 protein (mean ± 
SEM, n=6). * Different from L6 and Con siRNA, P<0.05.  (B) Representative 
immunoblot.  (C-F) L6 myotubes were transfected with control siRNA or SCD1 siRNA, 
differentiated for 3 days and assessed for fatty acid metabolism using 0.5 mM 3H-
palmitate conjugated to 2% fatty acid-free bovine serum albumin. Results are expressed 
as nM/h total palmitate uptake (C), palmitate oxidation (D), palmitate incorporation into 
triacylglycerol (E) or incorporation into diacylglycerol (F) and represent mean SEM 
(n=6 individual wells). * P<0.05 as assessed by unpaired t-test.  
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Figure 4.3 SCD1 siRNA increased ceramide and diacylglycerol content in L6 
myotubes. Ceramide (A) and diacylglycerol (B) content were assessed in myotube 
lysates after 5 h incubation with BSA alone or 0.5 mM palmitate conjugated to 2% fatty 
acid-free BSA.  Results are expressed as fold change relative to Con siRNA Vehicle and 
represent mean ± SEM (n=10 individual wells). * P<0.05 vs Vehicle, † P<0.05 vs 
Vehicle within the same group. 
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SCD1 knockdown induces insulin-resistance in L6 myotubes 
 
The effects of SCD1 siRNA on glucose uptake was assessed in the presence and 
absence of palmitate and insulin.  Basal 2DG uptake was not different between control 
and SCD1 siRNA treated cells (Figure 4.4A).  Insulin-stimulated 2DG uptake was 
increased by ~70% above basal in control siRNA L6 myotubes, which is consistent with 
previous values reported for this cell line (Sinha et al., 2004).  SCD1 siRNA abrogated 
the insulin-stimulated 2DG uptake observed in control cells, which coincided with 
ceramide and DAG accumulation (Figure 4.4A).  Treating L6 myotubes with 0.5 mM 
palmitate for 5 h blunted insulin-stimulated 2DG uptake in control cells and 2DG 
uptake remained at basal rates in SCD1 siRNA cells.  Akt Ser473 phosphorylation, a 
critical downstream event in insulin signal transduction was increased by insulin and 
was partially blunted by palmitate treatment in both groups (Data not shown).  Akt 
Ser473 phosphorylation was higher in control vs. SCD1 siRNA in response to insulin 
(Figure 4.4B).  Insulin-stimulated Akt Thr308 phosphorylation was blunted 32% and 
54% by palmitate in control and SCD1 siRNA myotubes, respectively.  Collectively, 
these data demonstrate that SCD1 is essential for the maintenance of normal insulin-
stimulated glucose transport in L6 myotubes. 
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Figure 4.4 Glucose uptake and insulin signalling are attenuated by SCD1 siRNA.  
L6 myotubes were transfected with control siRNA or SCD1 siRNA and differentiated 
for 3 days.  (A) 2-deoxyglucose uptake was assessed in myotubes following 5 h 
treatment with 2% fatty acid free BSA or 0.5 mM palmitate conjugated to 2% fatty 
acid-free BSA, with or without 100 nM insulin.  (B) In similar experiments, myotubes 
were treated as described above and were lysed.  Lysates were probed for phospho-Akt 
Ser 473 protein content. * P<0.05 vs Vehicle within the same group, † P<0.05 vs Con 
siRNA Palmitate. 
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SCD1 overexpression attenuates lipid metabolite accumulation in L6 myotubes 
The initial experiments demonstrated that SCD1 protected L6 myotubes from insulin 
resistance by preventing the accumulation of lipid metabolites; however, the addition of 
palmitate resulted in insulin resistance.  To investigate whether SCD1 protects 
myotubes from palmitate-induced insulin resistance, L6 myoblasts were transiently 
transfected with pcDNA3.1/Hygro-mSCD1 (L6 SCD1) or control (L6) then rapidly 
differentiated into myotubes. SCD1 protein content in fully differentiated myotubes was 
increased 1.35-fold (Figure 4.5B).  Interestingly, the fold increase observed in L6 
myotubes was similar to the increase seen in obese, insulin resistant rodents compared 
with lean littermates (Figure 4.1).  SCD1 overexpression did not affect palmitate uptake 
(Figure 4.5C) and resulted in a small (12 ± 1%), yet significant decrease in oxidation 
(Figure 4.5D).  SCD1 overexpression reduced the incorporation of palmitate into DAG 
by 90% whereas label recovery in TAG was 40% greater (Figure 4.5E-F).  There was 
no difference in ceramide and DAG contents with SCD1 overexpression when cells 
were incubated in FA-free media (Figure 4.6A-B).  Consistent with the 3H -palmitate 
incorporation experiments, ceramide and DAG content were elevated 4-fold in control 
cells, whereas SCD1 overexpression attenuated this increase by ~50% (4.6A-B).  Thus, 
despite small decreases in fatty acid oxidation, SCD1 overexpression results in 
partitioning of fatty acids into TAG and limits the flux of palmitate into ceramides and 
DAG. 
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Figure 4.5 Transient SCD1 overexpression in L6 myotubes attenuates diacylglycerol 
esterification but results in triacylglycerol esterification.  L6 myoblasts were transfected 
with SCD1 or an empty vector for 20 h and cells were differentiated for 3 days.  (A) 
SCD1 mRNA assessed after 24 h by RT-PCR. (B) SCD1 protein.  * P<0.05 vs L6 as 
determined by unpaired t-test. (C-F) Fatty acid metabolism was assessed using 0.5 mM 
3H-palmitate conjugated to 2% fatty acid-free BSA.  Results are expressed as nM/h total 
palmitate uptake (C), palmitate oxidation (D), palmitate incorporation into TAG (E), or 
incorporation into DAG (F) and represent mean SEM (n=10 individual wells). * P<0.05 
as assessed by unpaired t-test. 
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Figure 4.6 Effect of transient SCD1 overexpression on lipid metabolite content. 
Ceramide (A) and diacylglycerol (B) content were assessed in myotube lysates after 5 h 
incubation with BSA alone or 0.5 mM palmitate conjugated to 2% fatty acid-free BSA.  
Results are expressed as fold change relative to L6 Vehicle and represent mean SEM 
(n=6 individual wells). * P<0.05 vs Vehicle, † P<0.05 vs L6. 
A
B
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SCD1 overexpression protects L6 myotubes from FA-induced insulin resistance 
2-DG uptake in L6 SCD1 myotubes was increased both basally (20%) and following 
insulin stimulation (14%) compared with native L6 myotubes (Figure 4.7A).  The net 
increase in 2-DG uptake in response to insulin was not different between cells.  There 
were no differences in the phosphorylation of Akt (Figure 4.7B).  To examine whether 
SCD1 protects myotubes from insulin resistance in the presence of excess saturated 
fatty acids, cells were incubated for 5 h with 0.5 mM palmitate.  While ~75% of the 
insulin-stimulated glucose uptake was lost in L6 myotubes pre-treated with palmitate, 
only 35% of the insulin-stimulated glucose uptake was lost in L6 SCD1.  Palmitate 
decreased insulin-stimulated Akt Ser 473 phosphorylation to a greater extent in L6 
(35%) compared with L6 SCD1 cells (20%) (Figure 4.7B).  Insulin-stimulated Akt 
Thr308 phosphorylation was decreased by 51% in L6 and 35% L6 SCD1 myotubes.  
There was no difference in total Akt protein (data not shown).  Taken together, these 
results indicate that SCD1 partially protects skeletal muscle cells from fat-induced 
insulin resistance by blunting the suppressive effects of palmitate on the 
phosphorylation of Akt. 
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Figure 4.7 Glucose uptake and insulin signalling with SCD1 overexpression.  
(A) 2-deoxyglucose uptake was assessed in myotubes following 5 h treatment with 2% 
fatty acid free BSA or 0.5 mM palmitate conjugated to 2% fatty acid-free BSA, with or 
without 100 nM insulin.  (B) In similar experiments, myotubes were treated as 
described above and were lysed.  Cell lysates were probed for phospho-Akt Ser 473 
protein content. * P<0.05 vs Vehicle within the same group, † P<0.05 vs L6. 
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Serine kinase activation is influenced by SCD1 expression 
The production of fatty acid metabolites within insulin responsive tissues is known to 
activate a host of serine kinases including IκBα, NFκB and JNK, which have been 
shown to impair insulin signal transduction at IRS-1 Ser 307 and glucose disposal (Yu 
et al., 2002; Gao et al., 2003).  The effect of SCD1 protein content on the 
phosphorylation of JNK was determined.  For all protein determinations, total protein 
contents were not different between conditions.  In siRNA experiments, basal JNK 
phosphorylation was unaffected by SCD1 siRNA, whereas palmitate pre-treatment 
increased JNK phosphorylation to a greater degree in SCD1 siRNA compared with 
control siRNA L6 myotubes (Figure 4.8A).  In overexpression experiments, JNK 
phosphorylation was not different in the basal state between L6 and SCD1 L6 myotubes 
(Figure 4.8C).  Palmitate preincubation increased JNK phosphorylation in L6 myotubes, 
whereas no increase occurred in L6 SCD1 cells.  The activation of the proinflammatory 
IκBα and NFκB was determined by measuring Ser 32 phosphorylation of IκBα, which 
indicates targeting of IκBα for degradation and nuclear translocation of NFκB.  SCD1 
siRNA resulted in increased phosphorylation of IκBα, both basally and with palmitate 
pre-treatment (Figure 4.8B), whereas overexpression of SCD1 protected L6 myotubes 
from palmitate-induced IκBα phosphorylation (Figure 4.8D). 
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Figure 4.8 Serine kinase activation with SCD1 knockdown and overexpression.  
(A-B) L6 myotubes were transfected with control siRNA or SCD1 siRNA, then 
differentiated for 3 days. (C-D) L6 myoblasts were transfected with mock or SCD1 
plasmids and differentiated for 3 days.  Cells were exposed to control (2% BSA) media 
or 0.5 mM palmitate conjugated to 2% fatty acid-free BSA for 5 h. Myotubes were 
lysed in ice-cold buffer and subjected to SDS-PAGE and analysis of JNK 
phosphorylation (A and C) and IκBα phosphorylation (B and D) using polyclonal 
antibodies. * P<0.05 vs Vehicle within the same, † P<0.05 vs L6 SCD1 or SCD1 siRNA 
Palmitate where applicable. 
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4.4 Discussion 
The above data demonstrate that SCD1 expression is elevated in the skeletal muscle of 
obese and diabetic rodents.  SCD1 inhibition in L6 myotubes increased the 
accumulation of lipid metabolites, resulted in serum kinase activation and insulin 
resistance.  In case of SCD1 overexpression, TAG esterification was increased whereas 
DAG and ceramide accumulation and serum kinase activation were reduced.  These 
events were associated with protection from fatty acid-induced insulin resistance.  
Collectively, these data indicate that SCD1 protects skeletal muscle from lipotoxicity in 
the face of a high fat challenge.  
 
Studies of mice with global genetic ablation of SCD1 (Cohen et al., 2002; Ntambi et al., 
2002a) as well as mice treated with SCD1 antisense oligonucleotides inhibitors (Jiang et 
al., 2005a) have implicated SCD1 as a cause of obesity and insulin resistance.  SCD1-/- 
mice are resistant to diet induced weight gain (Cohen et al., 2002; Ntambi et al., 2002a), 
have improved insulin signalling (Cohen et al., 2002; Rahman et al., 2003; Rahman et 
al., 2005) and increased fatty acid oxidation (Dobrzyn et al., 2005) and reduced fatty 
acid synthesis (Jiang et al., 2005a).  But along with these positive effects knockdown 
models also developing undesirable genetic changes to compensate for the loss of 
SCD1.      
 
The aim of these studies originated from conflicting observations.  First, the primary 
role of SCD1 is to convert saturated fatty acids (primarily 16:0, 18:0) to 
monounsaturated fatty acids (16:1, 18:1) (Ntambi & Miyazaki, 2004).  Second, 
incubating cells with saturated fatty acids leads to insulin resistance, secondary to 
increases in ceramide and DAG content (Schmitz-Peiffer et al., 1999; Montell et al., 
2001; Chavez et al., 2003b).  Third, global SCD1 ablation reduces skeletal muscle 
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ceramide accumulation (Dobrzyn et al., 2005) and improves insulin signalling and 
glucose tolerance (Rahman et al., 2003).  To investigate the role of SCD1 in fat 
metabolism and the interaction with insulin action, experiments were conducted in L6 
skeletal muscle myotubes with reduced (~60% of control), normal (100%) and elevated 
(135%) SCD1 protein content.  Altering SCD1 protein content in L6 myotubes induced 
modest changes in fatty acid uptake and oxidation, changes that are unlikely to underpin 
the observed changes in lipid metabolites discussed herein.  Ceramide and DAG were 
markedly elevated in SCD1 deficient cells, even when excess palmitate was not present 
in the culture media, suggesting a role of SCD1 in resulting lipid metabolism.  
Moreover, increasing SCD1 content largely prevented the palmitate-induced increase in 
ceramide and DAG.   
 
Although the finding of the  role of SCD1 is consistent with other studies in different 
cell types  (Hulver et al., 2005) recently suggested that elevated expression of SCD1 in 
skeletal muscle contributes to abnormal lipid metabolism and the aeitology of obesity.  
While our data largely support these observations (Figure 4.5E), TAG accumulation per 
se is unlikely to cause insulin resistance (Kelley et al., 2002) or lipotoxicity (Busch et 
al., 2005), and in fact may provide a protective role by providing a sink for the 
deposition of  fatty acyl-CoA metabolites.  
 
In the present study, insulin-stimulated 2-deoxyglucose uptake was completely blunted 
in SCD1 siRNA cells, which occurred concomitantly with elevated ceramide and DAG 
levels.  Moreover, these experiments demonstrate that basal levels of SCD1 cannot 
prevent palmitate-induced insulin resistance in muscle cells.  Moreover, these 
experiments demonstrate that basal levels of SCD1 cannot prevent palmitate-induced 
insulin resistance in muscle cells.  In contrast, overexpressing SCD1 prevented most of 
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the palmitate-induced reduction in insulin-stimulated glucose uptake, most likely via 
inhibition of ceramide accumulation.  Ceramides negatively regulate insulin action 
downstream of PI 3-kinase by PP2A and PKCζ mediated dephosphorylation of Akt and 
preventing Akt plasma membrane recruitment (Powell et al., 2003; Powell et al., 2004; 
Stratford et al., 2004).  The finding of reduced Akt Ser-473 and Thr-308 
phosphorylation indicates that ceramide accumulation contributes to the palmitate 
suppression of glucose uptake in L6 myotubes (data not shown).  JNK and the inhibitor 
of IκB kinase (IKK) pathways are also activated by fatty acids and directly interfere 
with insulin signal transduction (Yuan et al., 2001; Yu et al., 2002).  Further studies 
examining IRS-1 serine and tyrosine phosphorylation are warranted.   
 
In summary, the present findings provide a novel perspective on the tissue specific role 
of SCD1. Reducing SCD1 expression increases ceramide and DAG accumulation in L6 
muscle myotubes exacerbates pro-inflammatory signalling and promotes insulin 
resistance.  In contrast, overexpression of SCD1 provides a protective effect against FA-
induced insulin resistance by limiting lipid metabolite accumulation and serine kinase 
activation.  Thus, SCD1 may be elevated in skeletal muscles of obese animals to 
prevent the accumulation of fatty acyl-CoA metabolites that directly contribute to 
insulin resistance.   
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CHAPTER 5 
GENERAL DISCUSSION 
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The objectives of this thesis were (1) to examine the effects of fatty acid subtype on 
fatty acid-induced insulin resistance and skeletal muscle SCD1 content and activity, and 
(2) to determine the role of SCD1 on substrate metabolism and fatty acid-induced 
insulin resistance in L6 myotubes in vitro. 
 
The initial rodent study (Chapter 3) was conducted to examine the effects of dietary 
fatty acid subtype on skeletal muscle fatty acid metabolite accumulation and insulin 
resistance in vivo.  This was based on several observations.  Firstly, studies in rodents 
and humans demonstrate that diets high in saturated fatty acids induce insulin 
resistance, whereas diets high in unsaturated fatty acids generally have a less 
pronounced, or no effect on insulin-stimulated glucose disposal (Montell et al., 2001; 
Riccardi et al., 2004).  Secondly, DAG and ceramide accumulate in response to 
palmitate, but not oleate, exposure in skeletal muscle myotubes (Chavez et al., 2003b) 
and these fatty acid metabolites are known to interfere with insulin signalling.  Thus, it 
was hypothesised that dietary saturated fatty acid induce insulin resistance in vivo due to 
the accumulation of ceramides and DAG in skeletal muscle.  Results from this study 
showed that diets high in saturated fatty acids induce insulin resistance, which is 
associated with increased skeletal muscle DAG content.  In contrast, a diet high in 
polyunsaturated fatty acids actually improved insulin sensitivity and resulted in marked 
increases in TAG with a modest increase in DAG.  The ceramide content in both groups 
of rats fed high fat diets was not affected by composition, which contrasts previous 
studies indicating that ceramides cause insulin resistance (Turinsky et al., 1990; Adams 
et al., 2004; Gorska et al., 2004; Straczkowski et al., 2004).  Collectively, these data 
indicated that the dietary fat subtype plays an important role in inducing insulin 
resistance, rather than fatty acid oversupply per se.  
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An interesting observation from the studies in insulin resistant rodents was the marked 
increase in SCD1 mRNA, protein and activity with SAT (Figure 3.4A and B).  These 
data are consistent with previous studies in rodents that implicate SCD1 is the aetiology 
of insulin resistance / type 2 diabetes (Cohen et al., 2002; Ntambi et al., 2002a).  
However, an alternative interpretation is that SCD1 is increased in these models as a 
consequence of increases in fatty acid fluxes / insulin resistance to prevent further 
deleterious events / lipotoxicity.  Indeed, studies in other cell lines including chinese 
hamster ovary cells (Listenberger et al., 2001), showed that SCD1 affords protection 
from palmitate induced lipotoxicity.  Whilst previous studies in mice with global SCD1 
deletion indicate that SCD1 deficiency results in a leaner, more insulin sensitive 
phenotype; these studies are complicated by the findings of concomitant increases in 
basal energy expenditure and thermogenesis (Lee et al., 2004b).   
 
Accordingly, an experiment was designed to directly examine the role of SCD1 on 
skeletal muscle fatty acid metabolism and insulin sensitivity.  A transient in vitro design 
(ie: L6 myotubes) was implemented to allow for the determination of a tissue specific 
response and circumvent potential changes associated with genetic/stable SCD1 
ablation (eg: increases in fatty acid oxidation proteins).  This study does not, however, 
allow for valid conclusions to be made regarding the in vivo environment.  The 
hypothesis of this study was that SCD1 deficiency would result in the accumulation of 
fatty acid metabolites within skeletal muscle, which would cause insulin resistance, 
whereas overexpression would protect from fatty acid induced insulin resistance by 
preventing the accumulation of fatty acid metabolites.  
 
Altering SCD1 content in vitro in skeletal muscle myotubes had only minor effects on 
fatty acid oxidation and fatty acid uptake.  Rather, decreasing SCD1 in vitro resulted in 
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increased esterification of palmitate into DAG and ceramide whereas increasing SCD1 
expression prevented increases in these lipid metabolites and instead resulted in TAG 
accumulation.  This is consistent with the role of SCD1 in desaturating fatty acids and 
the preference of DGAT, the terminal enzyme in TAG esterification, for unsaturated 
fatty acids.  It was also shown that SCD1 in vitro is essential for the maintenance of 
insulin signalling in L6 myotubes, even in the absence of an exogenous fatty acid load.  
Moreover, native L6 myotubes were unable to cope with a palmitate load and became 
insulin resistant, whereas SCD1 in vitro overexpression partially protects cells from 
palmitate-induced insulin resistance.  These findings are consistent with a protective 
role of SCD1 against lipotoxicity in several other cell types (Listenberger et al., 2003; 
Busch et al., 2005; Scaglia & Igal, 2005) and contradicts SCD1 knockout model studies 
(Cohen et al., 2002; Ntambi et al., 2002b; Jiang et al., 2005a).  Some authors (Hulver et 
al., 2005) have suggested that elevated skeletal muscle SCD1 expression contributes to 
abnormal lipid metabolism and the aetiology of obesity.  In this previous study 
conducted in primary human myotubes (Hulver et al., 2005), SCD1 overexpression 
decreased fatty acid oxidation and increased TAG synthesis.  While our data largely 
support these observations, TAG accumulation per se is unlikely to cause insulin 
resistance (Kelley et al., 2002) or lipotoxicity (Listenberger et al., 2003; Busch et al., 
2005; Scaglia & Igal, 2005), and in fact may provide a protective role by providing a 
reservoir for the deposition of other fatty acyl-CoA metabolites.  Importantly, our data 
extend on these previous observations and indicate that TAG accumulation in SCD1 
overexpressing cells protects cells from DAG and ceramide accumulation.  Thus, the 
induction of SCD1 in skeletal muscle of obese, insulin resistant phenotypes may be a 
consequence rather than a cause of insulin resistance and may be initiated to prevent the 
progression of insulin resistance.  
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In chapter 3, insulin-stimulated 2-deoxyglucose uptake was abrogated in SCD1 siRNA 
cells and endogenous levels of SCD1 did not prevent palmitate-induced insulin 
resistance.  In contrast, overexpressing SCD1 prevented most of the palmitate-induced 
reductions in insulin-stimulated glucose uptake, possibly via inhibition of ceramide 
accumulation.  Ceramides negatively regulate insulin action downstream of 
phosphatidylinositol 3-kinase by protein phosphatase 2A and protein kinase Cζ 
mediated dephosphorylation of Akt and preventing Akt plasma membrane recruitment 
(Powell et al., 2003; Powell et al., 2004; Stratford et al., 2004).  The finding of reduced 
Akt phosphorylation and activity indicates that ceramide accumulation contributes to 
the palmitate mediated suppression of glucose uptake in L6 myotubes.  Thus, elevated 
ceramide synthesis and suppressed Akt action appear to contribute to the palmitate-
induced insulin resistance. However, all these studies supports the hypothesis that SCD1 
protects muscle cells from FA-induced insulin resistance by reducing ceramide and 
DAG accumulation.  This interpretation supports the model of cellular lipid metabolism 
where TAG accumulation protects against lipotoxicity.  
 
In conclusion, this thesis has demonstrated that SCD1 is elevated in the skeletal muscle 
of obese, insulin resistant rodents.  While previous studies in global SCD1 knockout 
mice indicate that SCD1 is causative for insulin resistance, the results presented in this 
thesis indicate that reducing SCD1 causes insulin resistance and SCD1 overexpression 
protects skeletal muscle myotubes from fatty acid-induced insulin resistance.  Thus, 
future studies should examine the role of SCD1 independent of the secondary effects 
associated with global SCD1 deletion. One such approach would be to examine skeletal 
muscle insulin sensitivity in mice with targeted disruption and / or overexpression of 
SCD1 in skeletal muscle.    
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